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Abstract 
 
Functional nucleic acids (FNA), including nucleic acids catalysts (ribozymes and 
DNAzymes) and ligands (aptamers), have been discovered in nature or isolated in a 
laboratory through a process called in vitro selection. They are nucleic acids with 
functions similar to protein enzymes or antibodies. They have been developed into 
sensors with high sensitivity and selectivity; it is realized by converting the reaction 
catalyzed by a DNAzyme/ribozyme or the binding event of an aptamer to a fluorescent, 
colorimetric or electrochemical signal. While a number of studies have been reported for 
in vitro sensing using DNAzymes or aptamers, there are few reports on in vivo sensing or 
imaging. MRI is a non-invasive imaging technique; smart MRI contrast agents were 
synthesized for molecular imaging purposes. However, their rational design remains a 
challenge due to the difficulty to predict molecular interactions. Chapter 2 focuses on 
rational design of smart T1-weighted MRI contrast agents with high specificity based on 
DNAzymes and aptamers. It was realized by changing the molecular weight of the 
gadolinium conjugated DNA strand with the analytes, which lead to analyte-specific 
water proton relaxation responses and contrast changes on an MRI image. The designs 
are general; the high selectivity of FNA was retained. 
Most FNA-based fluorescent sensors require covalent labeling of 
fluorophore/quencher to FNAs, which incurrs extra expenses and could interfere the 
function of FNAs. Chapter 3 describes a new sensor design avoiding the covalent 
labeling of fluorophore and quencher. The fluorescence of malachite green (MG) was 
regulated by the presence of adenosine. Conjugate of aptamers of MG and adenosine and 
a bridge strand were annealed in a solution containing MG. The MG aptamer did not bind 
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MG because of its hybridization to the bridge strand, resulting in low fluorescence signal 
of MG. The hybridization was weakened in the presence of adenosine, leading to the 
binding of MG to its aptamer and a fluorescence increase. The sensor has comparable 
detection limit (20 µM) and specificity to its labeled derivatives. 
Enzymatic activity of most DNAzymes requires metal cations. The research on 
the metal-DNAzyme interaction is of interest and challenge to scientists because of the 
lack of structural information. Chapters 4 presents the research on the characterization of 
the interaction between a Cu2+-dependent DNAzyme and Cu2+. Electron paramagnetic 
resonance (EPR) and UV-Vis spectroscopy were used to probe the binding of Cu2+ to the 
DNAzyme; circular dichroism was used to probe the conformational change of the 
DNAzyme induced by Cu2+. It was proposed that the conformational change by the Cu2+ 
binding is important for the activity of the DNAzyme. Chapter 5 reports the dependence 
of the activity of 8-17 DNAzyme on the presence of both Pb2+ and other metal cations 
including Zn2+, Cd2+ and Mg2+. It was discovered that presence of those metal cations can 
be cooperative or inhibitive to 8-17 activity. It is hypothesized that the 8-17 DNAzyme 
had multiple binding sites for metal cations based on the results. 
Cisplatin is effective killing tumor cells, but with significant side effects, which 
can be minimized by its targeted delivery. Chapter 6 focuses on the effort to functionalize 
liposomes encapsulating cisplatin by an aptamer that selectively bind nucleolin, an over-
expressed protein by breast cancer cells. The study proved the selective cytotoxicity to 
breast cancer cells of the aptamer-functionalized liposome. 
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Chapter 1 Introductions of functional nucleic acids, magnetic 
resonance imaging (MRI) and electron paramagnetic resonance 
(EPR) 
 
1.1 Functional nucleic acids 
 
Nucleic acids were discovered and isolated 150 years ago by Johann Friedrich 
Miescher and Richard Altman. They were not recognized as nature-selected gene carriers 
until an important discovery by Erwin Chargaff in the 1950s, which inspired research into 
both their chemistry and biological functions. The discovery of the helical structure of 
nucleic acids is recognized as the beginning of molecular biology.1 
In the intervening time since these foundational discoveries, it has been 
established that there are two categories of nucleic acids in nature: deoxyribonucleic 
acids (DNA) and ribonucleic acids (RNA). Their structures are shown in Scheme 1.1. 
They are biopolymers whose units contain a ribose (for RNA) or deoxyribose (for DNA), 
a nucleobase, and a phosphate. In nature, DNA has four bases (adenine (A), cytosine (C), 
thymine (T), and guanine (G)) while RNA has uracil (U) instead of thymine (structures 
shown in Scheme 1.1). DNA carries genetic information. Most often, RNA transfers 
genetic information and play important roles in protein synthesis, but it also carries 
genetic information in some species, such as viruses. 
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Scheme 1.1 Structures of nucleic acids and bases 
 
 
As opposed to DNA, which forms a long, helical structure, RNA assumes more 
diverse secondary and three dimensional structures. These more diverse structures led to 
the  hypothesis that RNA might have functions beyond genetic information storage and 
transfer.2,3  This hypothesis was validated first by the discovery of ribozymes4-6 in the 
1980s and later by the discovery of riboswitches7-9. Ribozymes and riboswitches are 
naturally-occurring or laboratory-evolved RNAs with enzymatic activity and affinity 
toward specific targets, respectively. They are the natural RNA analogues of protein 
enzymes and antibodies. 
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A novel technique called in vitro selection was developed to evolve RNA with 
desired functions in the laboratory, enabling researchers to obtain ribozymes or RNA 
aptamers which had no natural precedents.10-17 The method could be applied to DNA, 
which led to the discovery of DNAzymes18-24 and DNA aptamers.21,25-29 DNAzyme and 
DNA aptamers refer to DNA molecules with catalytic activities and affinity to specific 
targets, respectively. Now, the term “functional nucleic acids” is used to describe the 
wide range of nucleic acids (ribozymes, DNAzymes, RNA aptamers, and DNA aptamers) 
with function beyond the traditional genetic storage and transfer roles. Functional nucleic 
acids have been widely applied in research, medicine, and industry. 
1.1.1 In vitro selection 
Although functional nucleic acids were originally found in nature, most functional 
nucleic acids have been evolved in the laboratory. The procedure to obtain functional 
nucleic acids is called in vitro selection,30-33 or the Systematic Evolution of Ligands 
through Exponential Enrichment (SELEX).34-36 
The in vitro selection of functional nucleic acids is similar to natural evolution. It 
starts with a pool of unique nucleic acids, and it is assumed that a nucleic acid with the 
favorable property – the winner – is included in the pool. In vitro selection is the 
systematic method used to isolate this winner.  
A typical in vitro selection is shown in Figure 1.1. After the pool, which contains 
1012 to 1014 different nucleic acid sequences, is generated, winners are separated from the 
rest of the pool. As the population of the winners is present at low abundance, 
polymerase chain reaction (PCR) is used to amplify the selected winners. This procedure 
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is called a round of selection. The amplified winners become the pool for the next round 
of selection. 
 
 
Figure 1.1 Schematic presentation of the procedure of in vitro selection 
To obtain functional nucleic acids, 10-20 rounds of selection are often 
necessary.30-33 This number of selection rounds is necessary because the winner is often 
not completely separated from the rest of the pool during each round of selection. 
Molecules without the needed properties can thus be amplified. However, the selection 
procedure enriches the winner population.  
The procedure presented above ensures the function of the winner. However, the 
selected winners might additionally have unfavorable properties. For instance, a 
DNAzyme which performs as a nuclease was selected by Lu lab. Its enzymatic activity 
requires the presence of Co2+ as cofactor. However, the selected pool has enzymatic 
activity with the presence of Co2+ as well as Zn2+ and Pb2+. Negative selection was 
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developed to enhance the selectivity of the functional nucleic acids.37 Similar to the 
regular selection, the process starts with a pool, in which the winners are already enriched. 
The molecules with the unfavorable properties are separated from the pool and discarded. 
The survived molecules are amplified and/or processed to the next round of selection. It 
has been reported that the selectivity can be significantly enhanced through negative 
selection.37 
After rounds of selection, the selected pool is then sequenced. The acquired 
sequences are analyzed and the sequence with the highest activity is truncated to obtain a 
new functional nucleic acid sequences. 
1.1.2 Aptamers 
The  term aptamer comes from the word “aptus”, which means “to fit”. It refers to 
nucleic acids which bind targets. The first aptamers were reported independently by the 
Gold group38 and the Szostak group.30 Aptamers have been selected toward various 
targets, such as small metal ions, organic molecules,10-12,26,39 peptides,40-42 proteins,25,43,44 
and even cells.45,46 They are the nucleic acid analogues of antibodies. However, they are 
superior to antibodies in terms of cost and stability. More importantly, aptamers are 
superior to antibodies in that they can be selected in vitro. Antibodies can only be 
generated in living organisms, and thus antibodies for certain toxins cannot be obtained. 
However, aptamers for these toxins would, in theory, be able to be selected in vitro.  
Although most RNA aptamers and all DNA aptamers were obtained through in 
vitro selection, aptamers were originally discovered in nature. Riboswitches was 
discovered in some mRNA. They contain a sequence which binds to a specific molecule. 
When the riboswitch binds to its target, it undergoes a conformational change which 
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changes the rate at which an adjacent gene is transcribed. Thus, the gene expression in 
this region is regulated by the riboswitch’s target molecule. Riboswitch explorations 
inspired research into functional nucleic acids, and today, it is the focus of many drug-
based interventions. 
1.1.3 Riozymes and deoxyribozymes (DNAzymes) 
Ribozymes and DNAzymes are the RNA and DNA analogues of protein enzymes. 
The first ribozymes were discovered in the 1980s by Cech and Altman.4-6 The Cech 
group discovered that introns were spliced in the absence of protein enzymes. It was 
proposed that a portion of the mRNA catalyzed the splicing. Altman identified that the 
RNA portion of an enzyme called RNase-P was essential for its enzymatic activity. Their 
pioneering work began the research into catalytic nucleic acids. 
Ribozymes are common in biological systems. They perform important roles in 
gene regulation and cellular physiology. Most naturally occurring ribozymes act as 
nucleases, catalyzing their own hydrolysis or the hydrolysis of other RNAs. In vitro 
selection enriched the library of ribozymes.47-50 For instance, Szostak and co-workers 
were the first to select an RNA molecule with ligase function.51  In vitro selected 
ribozymes also catalyze chemical reactions beyond ligation and cleavages, such as allyl 
transfer, alkylation, enantiomerization, Diels-Alder, and the metallation of 
mesoporphyrin IX.52  Although the reactions catalyzed by ribozymes are less diverse than 
those catalyzed by protein enzymes, in vitro selected ribozymes are uniquely important in 
the field of biocatalysis.  
DNA has less diverse conformations than RNA because of its lack of a 2'-
hydroxyl group. This could be the reason why catalytic DNA has not been discovered in 
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nature.  However, artificial catalytic DNA molecules, known as DNAzymes, have been 
obtained in the laboratory. DNAzymes are capable of catalyzing many of the same 
reactions as ribozymes.21,24,53-57  
1.1.4 Recent progress in the mechanistic studies of nucleic-acid-catalyzed 
reactions 
The function of nuclease-like DNAzymes requires the presence of metal ions. For 
instance, the 39E DNAzyme selected in our lab (secondary structure shown in Figure 1.2) 
is preferentially active in the presence of UO.2+,58,59 In the absence of uranyl, or in the 
presence of other metal ions, no activity is observed. This feature enhances the utility of 
the uranium sensor with high selectivity based on this DNAzyme. Because the metal ion 
cofactors of DNAzymes are central to their activity, much research has been carried out 
to characterize the interactions between DNAzymes and metal ions. 
DNAzymes are most often modeled as metalloenzymes with the DNAzyme-metal 
complex as the catalytically active specie.60 Michaelis-Menton models can be used to 
analyze a DNAzyme’s kinetics.59,61 For nuclease-like DNAzymes, the following 
reactions apply: 
E-S + M ↔ ES-M 
ES-M Æproduct + M 
In the equations, E, S and M are the enzyme strand, the substrate strand and the 
metal ion co-factor, respectively. 
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Figure 1.2 Secondary structures of several DNAzymes with nuclease activity predicted 
by mFold. 
 
It is assumed that the concentration of the intermediate, the DNA-metal complex, 
is constant. Its dissociation constant can thus be calculated through activity assays. While 
a DNA-metal complex has not yet been formally observed, the Michaelis-Menton62 
model explains the activity assay well and predicts the kinetics of the reactions catalyzed 
by DNAzymes accurately. 
Biophysical methods provide a powerful tool to characterize the metal-DNA 
interaction. The 8-17 DNAzyme (Figure 1.2) acts as a nuclease in the presence of Pb2+, 
Zn2+, and Mg2+.63  It can be modified with a fluorescent donor and acceptor in order to 
carry out biophysical studies. As a result, Förster Resonance Energy Transfer (FRET) 
studies64-67 can be carried out to observe the conformational changes induced in 
DNAzymes by metal cations. It was discovered that the conformational change produced 
by Zn2+ or Mg2+ was different from that of Pb2+.64,67,68 Zn2+ or Mg2+ led to the folding of 
the DNAzyme, followed by the catalytic cleavage, while Pb2+-induced cleavage did not 
involve the folding.  
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It has been reported that the presence of high concentrations (≥ 1 M) of 
monovalent metal ions such as Na+ and Li+ also activates DNAzymes.69 Based on this 
observation, it was proposed that the folding of the DNA instead of the specific binding 
of the metal ions activates the DNAzymes. It was even discovered that high 
concentrations of monovalent metal ions or millimolar Zn2+ and Mg2+ folds the 8-17 
DNAzyme into a Z-DNA conformation. Thus, it was hypothesized that the Z-DNA form 
is critical for 8-17’s activity.65 
The specific binding of DNAzymes to their metal ion cofactors has not been 
directly observed because these cofactors are colorless, prohibiting any spectroscopic 
characterization.  Before the crystal structure of the active DNAzyme-cofactor specie is 
solved, it is expected that advanced spectroscopic techniques such as EPR, NMR, and 
EAXFS will provide insight into the DNAzyme catalysis model. 
1.1.5 Functional nucleic acid-based sensors 
One of the most important applications of functional nucleic acids is their ability 
to detect species of interest such as metal cations, organic toxins and biological 
pathogens.70 Aptamers bind their targets with strong affinities, with Kds varying from the 
picolmolar to the micromolar range. More importantly, the binding of aptamers to their 
targets is specific, which makes aptamer-based sensors selective. Also, the high affinity 
between aptamers and targets ensures the high sensitivities of these sensors. 
DNAzymes can also be converted into biosensors.71 As discussed above, 
DNAzymes require cofactors, most often metal ions, for activity. Moreover, one metal 
cation is the main metal cofactor for each DNAzyme. In other word, the metal-DNAzyme 
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interaction is typically highly specific. The specificity of the DNAzyme-basd sensors 
hinges on this point. 
Although functional nucleic acids, especially DNA aptamers and DNAzymes, 
provide a platform for sensor design, the binding event of an aptamer to the target or the 
reaction catalyzed by a DNAzyme in the presence of its target must be transduced to a 
signal output.70 So far, fluorescent, colorimetric, electrochemical, and MRI contrast 
agents based on functional nucleic acids have been developed and reported.  
 
Fluorescent sensors  Shortly after the initial selection of aptamers by SELEX, 
efforts have been made to make sensors based on aptamers. Early efforts included 
functionalizing aptamers with fluorophores.72 The binding of the aptamer to the target 
was expected to affect the chemical surroundings of the fluorophore so that a 
fluorescence change could be detected. The first successful trial was reported by a group 
led by Ellington (Figure 1.3).73 A fluorescent dye was incorporated between G7 and G8, 
and a small fluorescent change could be detected in the presence of ATP. The 
fluorescence signal was not observed in the presence of other nucleotides.  
 
Figure 1.3 DNA aptamer that recognize ATP. The arrows point to the engineered bases 
for sensing. 
ACCTG‐G
TGGAGG
G
A
GGAGT
G‐GCG
A
T
T
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Figure 1.4 General designs for metal cation aptamer-based fluorescent sensors and 
DNAzyme-based sensors. 
 
Later, Li and co-workers reported a structural switching method.74-78 As shown in 
Figure 1.4, the sensor contained two strands: the aptamer strand (in black) labeled by 
fluorescein, and the quencher strand (in green) which was partially complementary to the 
aptamer strand. The two strands hybridized in solution and their fluorescence was 
quenched. However, the hybridization of these two strands is significantly destabilized by 
the presence of the analyte (adenosine, shown in orange). As a result, the quencher strand 
dissociated from the complex and the fluorescence was recovered. This is a general 
design for aptamer-based sensors and was adapted for other sensor designs. 
Fluorophore/quencher pairs were also applied in DNAzyme-based florescent 
sensors. The first example was reported by Li et al. in 2000.63 The 17E DNAzyme, which 
cleaves a DNA/RNA chimeric substrate strand in the presence of Pb2+, was developed as 
a Pb2+ sensor.79 As shown in Figure 1.4, the substrate strand was modified with a 
fluorophore and quencher while the enzyme strand was labeled with a quencher. The 
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hybridization of the enzyme to the substrate strand minimized the fluorescence, but the 
addition of the metal cation analyte activated the DNAzyme as a nuclease. As a result, 
the substrate was cleaved and released, leading to a recovery of the fluorescence. 
 
Colorimetric sensors  Although fluorescent sensors are sensitive and quantitative, 
they require a fluorometer. This makes it difficult to use these sensors onsite. In some 
cases, semi-quantitative, but fast and cheap detection is requested. To achieve this goal, 
colorimetric sensors based on functional nucleic acids were developed.70 
Gold nanoparticles have a deep red color.80 Generally, the smaller the 
nanoparticles are, the shorter their absorbance wavelength is. Thus, small gold 
nanoparticles (with radii around 10-20 nm) absorb light in the blue region, leading to a 
red color.81-83 It was also observed that as gold nanoparticles aggregate and form clusters 
micrometers in size, the resulting solution assumes a blue color. DNAzyme- and aptamer-
based colorimetric sensors are based on this phenomenon. 
 
Figure 1.5 (A) Colorimetric sensor for adenosine detection based on the regulation of 
the assembly of gold nanoparticles by the presence of adenosine. (B) A lateral flow device 
for adenosine detection based on the colorimetric sensor presented in A. 
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As shown in Figure 1.5A, a colorimetric adenosine sensor can be assembled by 
covalently functionalizing nanoparticles by two different DNAs, both of which are 
partially complimentary to the extended adenosine aptamer strand.84,85 When the different 
DNAs hybridize, the gold nanoparticles with different DNA functionalizations form 
aggregates, producing a faint blue  solution. The addition of adenosine switches the 
conformation of the aptamer strand. As a result, most of the aptamer strands bind to the 
target and the nanoparticle aggregates disassemble. Thus, a color change from faint blue 
to red can be observed in the presence of the analyte. The nanoparticle aggregates can 
also be disassembled by metal ions if DNAzymes are used, paving the way for 
colorimetric metal ion devices.86-91  
This nanoparticle-based colorimetric sensor was even converted to dip-stick 
device.92,93 As shown in Figure 1.5B, the DNA-assembled gold nanoparticle aggregate is 
loaded at the bottom of the device. The presence of the target disassembles the aggregate. 
Only the dispersed nanoparticles can flow up and be captured at the top of the dipstick, so 
when the analyte is present in solution, a red band forms at the top of the dipstick. 
 
Electrochemical sensors Electrochemical sensors based on functional nucleic acids 
have been developed. For instance, a group led by Plaxco reported the first 
electrochemical Pb2+ sensor using the 17E DNAzyme.94,95 First, the DNAzyme was 
immobilized on the surface of the gold electrode. Then the substrate strand was 
chemically modified by methylene blue (MB) and immobilized onto the surface of the 
electrode through DNA hybridization. The MB molecule on the surface of the electrode 
was capable of electron transfer and a current could be detected when the potential 
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applied to the electrode was scanned. When Pb2+ cleaves the substrate strand, the product 
carrying MB was released from the electrode, resulting in a decrease in the electric signal. 
By correlating the change in the Pb2+ concentration with the decreased current signal, 
they successfully detected Pb2+ in solution. 
Aptamers were also used in electrochemical sensors. The distance between the 
electrode and the electroactive species was regulated by the interaction of an aptamer 
with its analyte, leading to a detectable electrochemical signal.95-99 
 
1.2 Magnetic resonance imaging (MRI) 
MRI converts NMR-derived information into a meaningful image. NMR spectra 
provide information, such as chemical shift, J-J coupling and relaxation; relaxation time 
was utilized for imaging. After half a century of development, MRI is now a powerful 
tool in both clinical diagnosis and research. It was even more useful after the invention of 
MRI contrast agents.  
1.2.1 Principle of MRI 
Modern MRI uses the pulsed instead of the continuous wave technique. The 
operation procedure is described in Figure 1.6. In a magnetic field, the randomly directed 
(stage A) molecular magnetizations (M) align to achieve the lowest energy (stage B). An 
electromagnetic pulse will change the direction of the magnetization (to the x-y plate in 
stage C). As the pulse is very short, the magnetization tends to go back to the state with 
the lowest energy (relaxation, stage D). The magnetization can be decomposed into the 
transverse magnetization on x-y plate (MXY) and longitude magnetization on z axis (MZ). 
The amplitude of MZ and MXY (|M|XY) follow the equations 1.1 and 1.2: 
15 
 
ܯ௓ ൌ ܯ௓,଴ ቀ1 െ ݁
ି ೟
೅భቁ        (1.1) 
|ܯ|௑௒ ൌ ܯ௑௒,଴݁
ି ೟
೅మ         (1.2) 
T1 and T2 are the longitude and transverse relaxation time, respectively. They are 
the parameters that play the most important role in modern MRI technology. 
MRI was performed by scanning the MZ or MXY of the NMR-active nuclei of the 
imaged object. The images acquired are called T1- or T2-weighted MRI images. As 
presented in Figure 1.6, stage D, the spot with faster relaxation (short T1), has a higher 
MZ than the spot with slower relaxation. Thus, the spot with faster relaxation is brighter 
in a T1-weighted image than the spot with slower relaxation. 
 
 
Figure 1.6 Principle of the T1-weighted MRI imaging process. The magnetization of 
atoms aligns with the magnetic field. They are stimulated with a microwave pulse. The 
magnetization goes back to the state with the lowest energy with different rate. If the 
magnetization on the z-axis is scanned, the contrast on the image is dependent on the 
relaxation rate – fast relaxation leads to bright image. 
 
Theoretically, all the nuclei with non-zero magnetic moment are used for imaging; 
practically only the water proton is used for scanning. The reason for this is that water is 
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the most abundant specie in the human body. Moreover, hydrogen has the highest 
gyromagnetic ratio, which makes Hydrogen the most sensitive of all atoms.  
Finally, it is important to mention encoding. It is technically not possible to apply 
a pulse to a very small area. Thus, the signal from one pixel from the other should be 
differentiated. This process is called encoding. The most straightforward method for 
encoding is to apply a magnetic gradient. The chemical shift of the water proton signal is 
related to the magnetic field. If the gradient is applied, different spots will have different 
magnetic fields; thus, pixels can be differentiated through chemical shifts. Besides 
magnetic gradient, phase encoding is more widely used in modern MRI scanners. 
1.2.2 MRI contrast agents 
Contrast agents were developed to shorten the imaging time and enhance the 
contrast of the image. MRI contrast agents are chemicals which enhance the contrast of 
the MRI images.100 
It was discovered that most paramagnetic metal cations such as Fe3+, Cu2+ and 
Gd3+ can shorten T1 of water proton.100 Clinically Gd3+ compounds are used as contrast 
agents for T1-weighted scans because of its seven unpaired elections. 
 
Figure 1.7 Structures of the most widely used Gd-based MRI contrast agents: DTPA-
Gd and DOTA-Gd 
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Gd3+ hydrate is toxic, thus for biological applications it is necessary to complex it 
with a ligand that will reduce its toxicity.101 The most common ligands used for this 
purpose are DTPA102 and DOTA103 (structures shown in Figure 1.7).100 It has been 
reported that the pKd for DTPA-Gd and DOTA-Gd are 22.46 and 25.3 respectively.100 
The strong binding between Gd3+ and these ligands minimizes the release of free Gd3+ 
into the body leading to the reduced toxicity.  
The water proton relaxation enhancement by the Gd compound is dependent on 
the concentration. It is quantitatively described in Equation 1.3, in which T1 is the 
relaxation time of the water proton, T10 is the water proton relaxation time of pure water, 
[Gd] is the concentration of the gadolinium compound and r1 is defined as the 
compound’s relaxivity. 
ଵ
்ଵ
ൌ ଵ
்ଵబ
൅ ݎ1ሾܩ݀ሿ         (1.3) 
The Relaxivity of a gadolinium compound can be quantitatively described by the 
Solomon-Bloembergen-Morgan theory.100,104 The simplified model predicts Equation 1.4. 
ݎ1 ൌ ௤௉೘
்ଵ೘ାఛ೘
          (1.4) 
In Equation 1.4, Pm is the concentration of water proton, which is constant, q is 
the hydration number (the number of water molecules bound to each Gd cation), and τm is 
the lifetime of the bound water molecule. Finally, T1m is a fitted parameter (the bound 
water proton relaxation time), and is decided by factors such as the strength of the 
magnetic field and the size of the Gd compound. 
The Solomon-Bloembergen-Morgan theory precisely predicts the performance of 
the Gd-based MRI contrast agents and aids the design of contrast agents with high 
relaxivity and smart characteristics. 
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1.2.3 Smart MRI contrast agents 
Smart MRI contrast agents are produced by combining an MRI contrast agent 
with a sensor.105 Traditional MRI contrast agents enhance MRI contrast non-specifically. 
However, modern medical research and clinical applications require small molecules to 
be imaged with non-invasive techniques. Thus, using MRI/MRI contrast agents to image 
the distributions of small molecules attracted the attention of researchers. The relaxivity 
of smart MRI contrast agents can be regulated by the presence of small molecules, 
leading to differential contrast on an MRI image.105 
The Solomon-Bloembergen-Morgan theory provides a theoretical foundation for 
the development of the smart contrast agents. From Equation 1.4, the q and T1m are two 
parameters that can be regulated. q is related to the coordination of the Gd compounds, 
and T1m can be regulated by changing the size of the Gd compounds. 
One of the earliest smart MRI contrast agents was Ca2+-sensitive and invented by 
the Meade group.106 They successfully designed a Gd compound that also binds Ca2+. 
When this occurs, the binding coordination of the Gd3+ changes, and this translates into a 
relaxivity change. 
Today, few smart MRI contrast agents have been developed to recognize metal 
ions including Ca2+,106 Zn2+,107,108, Cu2+109 as well as H+,110 enzymes,111 oxygen, and 
other species of interest.112,113 The rational design of small contrast agents is still a 
challenge because their key molecular interactions are not well known or predictable.  
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1.3 Electron paramagnetic imaging (EPR) 
1.3.1 A Brief introduction to EPR  
Bleaney was the first to observe the electron resonance phenomenon.114 The EPR 
phenomenon is similar to NMR, in that electrons have spin (+1/2 or -1/2), and in a 
magnetic field, the energy of the electrons splits (Figure 1.8). The electromagnetic 
radiation whose energy is the difference between the splitting energy level can be 
absorbed, excites the electrons from the low-energy state to the high-energy state. The 
wavelength of the radiation is indicated in Equation 1.5. 
߭ ൌ
௚೐ഋಳಳబ
௛
          (1.5) 
In the equation, ge is the g-factor, which is decided by what chemical environment the 
electron belongs to. µB is the Bohr magneton, B0 is the magnetic field, and h is the Planck 
constant.  
 
 
Figure 1.8 The splitting of the electron spin energy level in the magnetic field and the 
absorbance of the microwave radiation. 
 
The absorbance happens only when the magnetic field (B0) and the frequency of 
the radiation (υ) meet Equation 1.5. The modern EPR spectrometer uses a fixed 
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wavelength. The magnetic field is scanned and the absorbance of the radiation is recorded. 
When Equation 1.5 is met, a peak can be observed.  
1.3.2 Applications of EPR in bioinorganic chemistry 
EPR is not applied as widely as NMR is. The reason is that EPR requires unpaired 
electrons. The electrons of most organic compounds are paired, and thus do not generate 
a detectable EPR signal. However, EPR is a very powerful tool to detect species with 
unpaired electrons, such as radicals and some transition metal compounds.115,116 As the g-
factors (ge) of unpaired electrons are sensitive to the binding ligand and binding geometry 
of the metal center, EPR can provide information about the interaction between metal 
cations and ligands. 
Bioinorganic chemistry studies the interactions between metal cations and 
biomolecules such as protein and nucleic acids, as well as metal-related catalysis. EPR is 
widely used in bioinorganic chemistry because it gives information about the energy 
splitting caused by biomolecular ligands as well as electron configuration. 
 
EPR in the study of metalloproteins The most common metal species found in 
proteins are Cu, Fe, Ni, Co, Mn, and Zn. EPR is a powerful tool to characterize proteins 
containing these metal cations, with the exception of Cu2+ and Zn2+.117-119 For instance, 
one of the most common metal cofactors in proteins is heme. EPR is one of the very few 
techniques that can distinguish a high-spin heme from a low-spin heme, since these 
heme’s spin states are decided by the binding strength of the axial ligand. By analyzing 
the available data systematically, Peisach and Blumberg even presented a “truth table,” 
which makes it possible to discern the category and orientation of the axial ligand by 
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simply analyzing and simulating the EPR spectra. Although it is a rough method, it does 
give important information about metal binding in macromolecules at an early stage of 
research.   
 
EPR in the study of nucleic acid structure and dynamics EPR is not as 
common in nucleic acid research as in protein research. The reasons are twofold. First, 
nucleic acids are EPR silent. Without spin labeling, no nucleic acid signal can be detected. 
Second, the binding between nucleic acids and metal ions is neither specific nor strong, 
and this broadens the metal cations’ EPR signal. However, EPR has been an important 
tool to study the folding and dynamics of nucleic acids.115,116,120-122  
  
1.4 Research focuses 
Research on the functional nucleic acids have two directions – their analytical, 
clinical and diagnostic applications and the characterizations of the specific interactions 
of the functional nucleic acids with other molecules which account for their functions. 
This dissertation focuses on both directions. 
Functional nucleic acids have been applied in the development of fluorescent, 
colorimetric, electrochemical sensors and smart T2-weighted MRI contrast agents. Thus, 
the first part of the dissertation focuses on converting the functional nucleic acids 
including aptamer and DNAzyme to smart T1 weighted MRI contrast agents. It was 
realized by transducing the binding event of the aptamer or the reaction catalyzed by the 
DNAzyme to the molecular weight change of the gadolinium compounds. At clinical 
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MRI magnetic field (1.5 T), the molecular weight change leads to the relaxation time 
change of water proton and a contrast change on an MRI image.  
The smart contrast agents responded to the analytes by decreased contrast (a 
“turn-off” signal). And the contrast agents required streptavidin, which is not cost-
effective. To solve the problems, a novel structure switching system was designed, in 
which two aptamers are conjugated together. Although the application of this structure 
switching has not been applied to the smart contrast agent designs, the concept was 
demonstrated by a label-free sensor based on the regulation of the fluorescence of 
malachite green. The presence of adenosine switches the structure of the aptamer of 
malachite green; and the aptamer is then able to bind to malachite green in the solution. 
Upon the binding, a fluorescence change can be detected. 
The metal cation-DNAzyme interaction was investigated in the dissertation, too. 
Spectroscopic techniques, such as electron paramagnetic resonance (EPR) can be used to 
characterize the interaction of Cu2+ and Cu2+-dependent DNAzyme. EPR of Cu2+ is 
sensitive to the binding mode; thus the technique has been applied to probe the binding of 
Cu2+ to various ligands including proteins. UV-Vis is another technique that can be used 
to investigate the binding. The UV-Vis absorbance of Cu2+ is dependent on the d-orbital 
splitting induced by the binding. The binding of Cu2+ to the DNAzyme can thus be 
probed through tracking the UV-absorbance band shifting. 8-17 DNAzyme has been 
characterized in multiple groups by multiple techniques. However, the enzymatic activity 
of the DNAzyme with the presences of two metal cations has not been reported. 
Fluorescence assay was used to characterize the DNAzyme activity with Pb2+ and other 
metal cations. 
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Finally, aptamers was used to functionalize liposome encapsulating anti-cancer 
medicine cisplatin. The functionalized liposome showed targeted drug delivery effect to 
the breast cancer cells over other cells. The delivery of the drug can be diminished by 
applying the antisense strand of the aptamer, which is useful in the case of over-dosing. 
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Chapter 2 Smart T1-weighted MRI contrast agents based on 
DNAzyme and aptamer for the detections uranyl cation and 
adenosine  
 
2.1 Introduction 
MRI contrast agents are chemicals that enhance the contrast on MRI images.1-4 As 
the MRI contrast corresponds to the magnetic relaxation of water protons, MRI contrast 
agents decrease the longitude relaxation time (T1) of water protons. 1,2,5 Among the 
contrast agents, gadolinium compounds are the most widely used T1-weighted contrast 
agents because of the unpaired electrons of Gd (III).1,2 Due to the toxicity of Gd3+, 
gadolinium chelates such as gadolinium-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic 
acid (DOTA-Gd) are usually used clinically.6,7  
A smart contrast agent is a combination of a sensor and an MRI contrast agent, 
which responds to the presence of analytes by a change of the relaxivity and thus a 
contrast change on an MRI image.8,9 Meade and coworkers pioneered this area by 
developing a contrast agent for the sensing of Ca2+.10,11 So far, the T1-weighted smart 
contrast agents have been developed for the recognitions of Ca2+,10,11 Zn2+,12,13 protons 
(pH),14,15 Cu2+,16 lactate17 as well as peptides18 and proteins19-21 such as β-glucuronidase22 
and Gal-80.18 Smart contrast agents have been even utilized to monitor enzymatic activity 
in vivo.23-26 However, very few smart contrast agents are available and the rational design 
of smart contrast agents with high specificity remains a challenge because the design 
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requires the detailed information of the interaction between gadolinium compounds and 
the target. In this chapter, the first rational design of smart T1-weighted MRI contrast 
agents is presented, which are based on functional DNA. The 39E DNAzyme and 
adenosine aptamer were used to demonstrate the concept. 
2.1.1 Adenosine aptamer and 39E DNAzyme 
39E is a DNAzyme or deoxyribozyme with nuclease activity.27,28 It is able to 
catalyze the hydrolysis of the substrate strand, 39S, which is a DNA/RNA chimeric 
strand, in the presence of the uranyl cation. The secondary structure of the 39E/39S is 
shown in Figure 1.2. The function of uranyl cation is unique and essential. Without the 
presence of uranyl, or with the presence of other metal cations, 39E is not catalytic active.  
39E was also isolated through in vitro selection. The DNAzyme has highest 
activity at pH 5.5. The kinetics assay indicated a high binding affinity between UO2+ and 
the DNAzyme, with the dissociation constant to be 463 nM. 39E has been developed into 
fluorescent and colorimetric sensors;27,29 the lowest detection limit was reported to be 45 
pM. 
The DNA aptamer for adenosine was isolated by Szostak and co-workers in 1995 
by in vitro selection.30 The dissociation constant was reported to be 6 µM. The adenosine 
aptamer has been widely used to prove the concepts of the novel designs of aptamer-
based sensors.31-38 Although the crystal structure of the aptamer has not been resolved, a 
great deal is known about the behavior of the adenosine aptamer.   
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2.1.2 Smart MRI contrast agents 
As discussed above, smart MRI contrast agents are the combination of MRI 
contrast agent and sensor.39,40 They have switchable relaxivity in response to the presence 
of the molecules of interest (analyte).  
One of the earliest smart MRI contrast agents was invented in 1999 for the 
recognition of Ca2+.10,11 As shown in Figure 2.1A, the contrast agent is composed of two 
modules, DOTA-Gd and the Ca2+ binding module. The Ca2+ binding module has four 
carboxyl groups; without the presence of Ca2+, the carboxyl groups bind to DOTA-Gd. 
The addition of Ca2+ switches the conformation of the contrast agent. As a result, the 
carboxyl groups bind to Ca2+ (Figure 2.1A). The vacancies for Gd3+ binding are then 
filled by water molecules. The hydration number is then switched from 0 to 1 and thus an 
increase in the relaxivity can be detected. 
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Figure 2.1 Smart MRI contrast agents for the sensing of Ca2+ (A) and β-galactosidase 
(B) 
 
The same design can be applied to smart contrast agents for the sensing of other 
metal cations, such as Zn2+ 12,13 and Cu2+.16 The critical step of the design is to find an 
analyte-binding module that can introduce the conformational change. In addition, the 
binding event should be selective to exclude false positive response. Because of the 
difficulties, very few cations can be monitored by smart MRI contrast agents. 
A
B
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Smart MRI contrast agent can also be used to monitor the enzymatic activity.22 
Meade and co-workers synthesized a DOTA-Gd derivative for the purpose (Figure 2.1B). 
The water binding position was blocked by the galactopyranose residue, which was so 
bulky that water can not bind to Gd3+. The saccharide residue can be removed by the 
presence of β-galactosidase (β-gal) and water can then bind to the gadolinium compound. 
The resulting increase of the hydration number leads to an increase of the relaxivity, and 
therefore the enhancement of the contrast on an MRI image.  
The regulation of the hydration number is straight forward, but not the only option. 
The Sherry group developed a contrast agent for detection of a protein called Gal80.18 
They successfully synthesized the conjugate of DOTA-Gd and a peptide that binds Gal80 
(G80BP). A relaxivity change resulted from binding of the contrast agent to the protein 
because of the change of the molecular weight and rotation correlation time of the 
gadolinium compound. 
T2-weighted smart MRI contrast agents have also been reported.41-43 Weissleder 
detected DNA and other bio-molecules by paramagnetic nanoparticle aggregates whose 
size can be regulated.44-48 The method was generalized by Yigit, M. V. et al when an 
aptamer strand was used as the probe DNA.49,50 The presence of the target disassembled 
the nanoparticle aggregates and induced a change of the contrast on an MRI image. 
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2.1.3 Rational design of the smart MRI contrast agents based on DNAzyme 
and DNA aptamer 
 
Figure 2.2 Schematic of the functional DNA-based smart MRI contrast agents for the 
sensing of uranyl cation (A) and adenosine (B) 
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It is desired to transform the cleavage of the substrate strand (39S) catalyzed by 
39E with the presence of UO22+ and the binding of adenosine aptamer to the adenosine 
into contrast changes on MRI images. Solomon-Bloembergen-Morgan theory predicts 
that the relaxivity of the gadolinium compound is regulated by the rotation correlation 
time. Larger molecules have longer rotation correlation time. Thus, changing the size of 
the gadolinium compound leads to a change of its relaxivity and therefore contrast of the 
MRI image. The rational design of functional DNA-based smart contrast agents is then 
based on the change of the size or molecular weight of the gadolinium compounds upon 
interaction with the target. 
The design of the 39E-based smart contrast agent is shown in Figure 2.2A. The 
enzymatic strand (in green) has a 3´-biotin modification, which is then coupled to 
streptavidin. DOTA-Gd was conjugated to the 5´ end of the substrate strand – 39S (in 
black). In solution, these two strands are hybridized and form a stable structure. With 
UO22+ present, 39S is cleaved; the cleaved product dissociates from the enzyme strand 
and streptavidin. The relaxivity of the gadolinium compound is then changed, leading to 
a contrast change on an MRI image. 
As shown in Figure 2.2B, the contrast agent for sensing adenosine has two DNA 
strands – the extended aptamer strand (aptamer strand) in black and red and Gd-strand in 
brown which is partially complimentary to the aptamer strand. The aptamer strand (in red) 
is biotylated and conjugated to streptavidin. The Gd-strand is conjugated to DOTA-Gd 
through NHS chemistry. As these two strands are hybridized in solution, the rotation 
correlation time of the Gd-strand is increased (with a molecular weight of about 70 kDa). 
Adenosine addition results in the structure switching and dissociation of the Gd-strand. In 
36 
 
the process, the molecular weight of the Gd compound is decreased to about 4 kDa. The 
T1 of water protons will increase, resulting in contrast changes on an MRI image as a 
result. 
2.2 Experimental  
2.2.1 Materials, equipment and DNA sequences 
All DNA molecules with biotin or amine modifications were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA). The DNA was standard desalted by 
the vendor and used without further purification. NHS activated DOTA was purchased 
from Macrocyclics, Inc. (Dallas, TX). Streptavidin and other chemicals were purchased 
from Sigma-Aldrich, Inc or Fisher Scientific, Inc.  
T1 was measured on a Bruker Minispec mq 60 MRI contrast agent analyzer (1.5 
T, Bruker), Varian NMR spectrometer (300 MHz) and 60 MHz - Varian EM360L NMR 
Spectrometer with Anasazi FT Upgrade. The MRI image was acquired on 1.5 GE Signa 
Horizon Echo Speed with 9.0 software (1.5 T, GE). 
The DNA sequences of the DNA used were obtained from previous reported 
literatures, and listed in Table 2.1. 
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Table 2.1 DNA sequences used in this chapter 
39E 5′-
CCATCTCTTCAGTCGGGTAGTTAAACCGACCTTCAGACATAGT
GAGT-biotin 
39S 5′-amine-ACTCACTATrAGGAAGAGATGG 
Ad-aptamer 5′-biotin-CACTGACCTGGGGGAGTATTGCGGAGGAAGGT 
Gd-strand 5′-CCAGGTCAGTG-amine 
 
2.2.2 Synthesis of the DNA-DOTA-Gd conjugates 
The conjugation of DOTA-Gd is realized through NHS chemistry. The synthesis 
process is presented in Figure 2.3. 
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Figure 2.3 Synthesis of the DOTA-Gd conjugated DNA strands 
NHS coupling of DOTA to DNA The optimized coupling conditions are described in 
this section. NHS activated DOTA was dissolved in acetonitrile at a concentration of 0.5 
mg/μL. Modified DNA was dissolved in 50 mM carbonate buffer (pH 10) at a 
concentration of 25 μM. Aliquotes of the NHS-DOTA solution (4 µL) were added into 1 
mL DNA solution once per hour for five hours. During the synthesis, the mixture was 
shaken gently at 4 °C. Shaking was continued for another 3 to 5 hours after the final 
addition. The product was then desalted on a C-18 cartridge (Sep-Pak, Waters) and 
checked by MALDI-MS. Typical yield for conjugated DNA with less than 20 bases is 
85%-95%. 
It is critical to keep the entire synthesis free from the metal contamination as 
DOTA is a strong chelator for almost all metal cations. If the contamination of metal 
cations, such as Zn2+, Cu2+ and Fe2+ occurs, it is difficult incorporate Gd3+ due to both 
kinetic and thermodynamic issues.  
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Incorporation of Gd into DNA-DOTA conjugates The DOTA conjugated DNA 
was dissolved in 50 mM acetate buffer (pH 5.55) at a concentration of 150 μM; GdCl3 
solution (10 mM) was added until the concentration reached 180 μM. GdCl3 and DNA-
DOTA solutions should be mixed slowly and evenly to avoid the precipitation. The 
solution was then kept at 75 °C for 30-45 min and the final product was purified by size 
exclusion chromatography (PD10, GE Health Care Life Sciences). The incorporation 
yield was 100%. 
The product cannot be purified by any reverse phase chromatography purification 
method as it has a strong affinity towards C18. Reverse phase HPLC and C18 affinity 
cartridge should be avoided for the purification. 
2.2.3 T1 measurement and MRI image acquisition 
Sample preparations  39E-based contrast agent was prepared by dissolving the 
DOTA-Gd coupled 39S and biotinylated 39E in 50 mM MES-Na (pH 5.5) buffer at a 
concentration of 30 µM. The solution was heated to 90 °C and cooled to ambient 
temperature over one hour. Streptavidin was then added into the solution at a 
concentration of 30 µM. Uranyl acetate (UO2OAc2) was added into the solution to reach 
various concentrations. EDTA (100 µM) was used to stop the reaction after 30 minutes. 
The sample was then subjected to T1 measurement. 
Adenosine aptamer-based contrast agent was prepared by dissolving the DOTA-
Gd coupled Gd-strand and aptamer strand in 50 mM Tris (pH 8.35), 300 mM NaCl and 5 
mM MgCl2 buffer at a concentration of 30 µM. The solution was heated to 90 °C and 
cooled to ambient temperature over one hour. Streptavidin was then added into the 
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solution at final concentration of 30 µM. Adenosine was added into the contrast agent 
solutions followed by T1 measurement. 
 
T1 measurement on Bruker Minispec relaxometer A Bruker Minispec mq 60 
MRI contrast agent analyzer (1.5 T, Bruker) was used to measure the longitude relaxation 
time of water protons. The temperature was kept at 37 ˚C during all T1 measurements. 
The parameters of the method are summarized in Table 2.2. 
Table 2.2 Parameters for the T1 measurements 
First 
Duration 
Last 
Duration 
Data 
points 
Duration 
Factor 
Total 
Analysis 
Del. 
Sam. 
Win. 
Sam. 
Win. 
Expon. 
Order 
150 ms 15 s 10 1.668 12.58 
min 
0.03 ms 0.03 s 1 
 
MRI image acquisition The Gd-strand (30 µM) and aptamer strand were dissolved 
in 50 mM Tris (pH 8.35), 300 mM NaCl and 5 mM MgCl2 buffer. The solution was 
heated to 90 °C and cooled to ambient temperature over one hour. Streptavidin was added 
into the solution at a concentration of 30 μM. Adenosine (5 mM) added into the solution 
as sample volume of 500 µL samples was used in the image acquisition. MRI image was 
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acquired at ambient temperature. The reverse and echo time were 400 ms and 14 ms, 
respectively. 
 
2.3 Results and discussion  
2.3.1 Synthesis of the DOTA-Gd conjugated DNA 
Although in the literature it was reported that neutral solution is the optimized 
condition for coupling through NHS chemistry,51,52 the incubation of amine modified 
DNA with the NHS ester did not lead to any reaction. The reason lies in the pKa of the 
amine group. The coupling reaction takes place by the nucleophilic attack of the amine 
group on the nitrogen atom of the NHS ester. The active species are the amine group (-
NH2), not the protonated amine group (-NH3+).  
Table 2.3 pKa of alkyl amines 
Name Molecular formula pKa 
Methylamine CH3-NH2 10.63 
Ethylamine C2H5-NH2 10.70 
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Propylamine C3H7-NH2 10.60 
Butylamine C4H9-NH2 10.77 
Pentanamine C5H11-NH2 10.59 
Hexylamine C6H13-NH2 10.56 
 
For the DNA coupling presented in Figure 2.3, it is important to calculate the 
minimum pH value when non-protonated amine group dominates. The pKa of the amine 
group modified at the termini of DNA was not reported. As there is C6H12 spacer between 
DNA and the amine group, it is reasonable to use the pKa values of the aliphatic amines. 
As shown in Table 2.3, they are about 10.6. Thus, it is concluded that at neutral pH, 
inactive protonated species dominate. Therefore pH 10 was selected for the reaction to 
minimize the protonated amine species. 
It is noted that the yield of the coupling of DOTA to DNA is sequence dependent. 
The yield reached 90% with a sequence length less than 20 bases; it decreased 
dramatically when the DNA is longer. For example, the coupling reaction of 17E, which 
has 34 bases, had yield lower than 10%. This phenomenon is ascribed to the fact that 
bases on the DNA strands can catalyze the hydrolysis of the NHS-ester. It has been 
reported that the NHS coupling reaction not only happened to aliphatic amines, but also 
Table 2.3 (cont.) 
43 
 
amine on the DNA bases.53 However, the conjugate on nucleobases is not stable, which 
leads to a spontaneous hydrolysis reaction. Therefore, DNA performs as a catalyst which 
accelerates the hydrolysis of the NHS ester, resulting in the decrease of the effective 
concentration of the active NHS ester.  
The traditional method for Gd incorporation, during which Gd(OH)3 and DOTA 
are kept at high temperature,  was shown to be an inappropriate choice. The Gd(OH)3 
solid can adsorb DNA molecules due to electrostatic interaction. Another difficulty of the 
incorporation is that Gd3+ binds to the phosphate backbone of DNA, leading to the 
precipitation of DNA molecules. 
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Figure 2.4 MS of the product after the coupling of DOTA (A) and the incorporation of 
Gd3+ (B) 
To avoid the precipitation, the buffer should contain a ligand that binds Gd3+. The 
affinity between buffer and Gd3+ should be lower than the affinity between Gd3+and 
DOTA to ensure incorporation. It was found that acetate buffer, pH 5.5, was the 
appropriate media. Heating to 75 ˚C was used to facilitate the reaction.  
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The mass spectrum of the product of the first step is shown in Figure 2.4A. There 
are two major peaks. The peak at 3534.7 is assigned unreacted Gd-strand and the peak at 
3920.8 is assigned to the DOTA coupled Gd-strand. The molecular weight difference of 
the two species (381.1) is consistent with the addition of DOTA.   
Figure 2.4B shows the MS of the DNA sample after the incorporation of 
gadolinium to the DOTA conjugated Gd-strand. The peak of 3540 is ascribed to 
unconjugated Gd-strand and the major peak with m/z of 4081 is ascribed to the DNA 
strand with DOTA-Gd conjugation. The difference of the molecular weight (540.81) is 
consistent with what is calculated (540). 
2.3.2 Activity of 39E under experimental conditions 
To our knowledge, the activity of 39E has not been reported at the high concentration (30 
µM). Streptavidin binds to uranyl non-specifically, which might lead to the decrease of 
the activity. To test the activity of 39E under current experimental conditions, 30 µM 39E 
and carboxyfluorecein labeled 39S was incubated with various concentrations of uranyl 
cation for 30 min. The reaction was quenched upon the addition of 8M urea and 100 mM 
EDTA and the product was analyzed by denaturing gel electrophoresis. The results are 
presented in Figure 2.5.  
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Figure 2.5 Activity assay of 30 µM 39E DNAzyme with the presence of 30 µM 
streptavidin 
In the presence of 0.5 µM uranyl, around 20% 39S was cleaved. With 10 µM 
uranyl the cleavage percentage is about 65%. Compared to literature, the activity of 39E 
is significantly decreased by the presence of streptavidin.28 Though the high 
concentration of DNA increased the absolute value of the reaction rate, the cleavage 
percentage is decreased. 
2.3.3 T1 Response of the 39E-based contrast agent 
The idea to regulate the longitude relaxation time of the water proton through 
regulating the size of the contrast agent was applied to the 39E DNAzyme. The smart 
MRI contrast agent for the sensing of uranyl cation was dissolved in 50 mM MES-Na 
buffer with a concentration of 30 µM. Metal cations (2 µM) were added into the solution 
and T1 was measured after overnight incubation.  
Concentration-dependent T1 response towards the uranyl cation As shown in 
Figure 2.6, it was observed that T1 increased from 1.5 s to almost 2 s. The T1 change 
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reached saturation at 2 µM uranyl cation. However, the linearity between T1 and the 
concentration of the uranyl cation was poor, but the quantification of the uranyl 
concentration is still possible. 
 
Figure 2.6 T1 response of the 39E-based contrast agent to the uranyl cation at various 
concentrations 
 
T1 change with the presence of metal cations The T1 responses to 10 µM various 
metal ions, including UO22+, Cd2+, Hg2+, Pb2+ and Zn2+,  are presented in Figure 2.7. As 
indicated in the figure, only the addition of UO22+ introduced 0.35 s increase for T1. The 
cleavage of 39S happened when uranyl cation was present and was detected by T1 
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measurement. Without the uranyl cation, or with other metal cations, no significant T1 
change was observed. 
 
Figure 2.7 The T1 responses of the 39E-based smart MRI contrast agents towards 
various divalent cations 
2.3.4 T1 Response of the adenosine aptamer-based contrast agent 
To confirm the adenosine sensing process shown in Figure 2.2, 30 μM of both 
DNA strands (including the biotinylated aptamer strand and DOTA-Gd conjugated Gd-
strand) were dissolved in buffer with 30 μM streptavidin. Adenosine was added to the 
solution to reach various concentrations. T1 measurement was carried on after more than 
30 min. 
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T1 responses with various concentrations of adenosine  As shown in Figure 
2.8, it was found that T1 increased from 1.43 s to 1.59 s when 0.5 mM adenosine was 
present. With an increase of adenosine concentration, T1 increased to 1.87 s when the 
concentration of adenosine was 5 mM. Adenosine concentration higher than 5 mM was 
not measured due to the poor solubility of adenosine. With 5 mM adenosine, around 35% 
decrease of relaxivity was observed.  
 
Figure 2.8 T1 response of the smart MRI contrast agent based on the adenosine 
aptamer in buffer (black) and 10% human serum (red). The inset presents the T1 response 
versus logarithm of the concentrations in buffer. 
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We also observed a linear relationship between T1 and the logarithm of adenosine 
concentration (inset of Figure 2.8). This linearity makes the semi-quantitative detection 
of adenosine feasible.  
In order to obtain the theoretical maximum signal increase, we dissolved 30 μM 
DOTA-Gd coupled Gd-strand and 30 μM streptavidin in buffer. Without the presence of 
the biotinylated aptamer strand, DOTA-Gd was not associated with streptavidin. It 
simulated the case when the Gd-strand was completely dissociated. T1 of the solution 
was 2.18 s. Not surprisingly, T1 response to adenosine did not exceed the limit, which 
indicated that the T1 response was from the structure switching.  
The concentration of streptavidin was varied. Without streptavidin, less than 0.1 s 
T1 increase was observed even with 5 mM adenosine (Figure 2.9A). The presence of 10 
µM streptavidin significantly enhanced T1 response to adenosine. The T1 response to 5 
mM adneosine reached maximum upon the presence of 20 µM or 30 µM streptavidin. 
This might be due to multiple biotin binding sites on streptavidin resulting in binding of 
multiple DNA strands. Streptavidin is necessary for the contrast agent to function. This is 
evidence that the T1 response observed is due to behavior of the system as displayed in 
Figure 2.2. 
 
Performance of the contrast agent responses in human serum  To test the 
performance of the contrast agent in human serum, the T1 response was measured in 10% 
human serum with various concentrations of adenosine. The results are plotted in Figure 
2.8 (red trace). 
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It was observed that T1 increased from 1.61 s when adenosine was absent to 1.96 
s with 3 mM adenosine. The contrast agent still responded to the presence of adenosine, 
even with human serum. However, it is worth noting that the contrast agent in human 
serum has a longer T1. This is probably because of the interaction of Gd compounds to 
the proteins in serum, such as albumin with a result of decreased hydration number. 
However, it did not affect the sensing in vivo.   
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Figure 2.9 (A) Streptavidin dependence the performance of the contrast agent, without 
which no T1 response can be observed. (B) Selectivity of the smart MRI contrast agent. 
53 
 
Selectivity of the contrast agent The T1 response of water protons induced by 
nucleosides other than adenosine was measured. The results are presented in Figure 2.9B. 
Different from adenosine, cytidine, guanosine or uridine did not increase T1. This is 
because the adenosine aptamer is specific; the Gd-strand was not released and almost no 
T1 change was observed. It was noted that the contrast agent had a slight negative T1 
response, ascribed to the viscosity change of the solution. Pyrimidine or purine at 
concentrations of 5 mM thickens the solution, leading to a longer rotation correlation 
time and drop of T1. The selectivity of the adenosine aptamer was inherited by the MRI 
contrast agent herein, which makes the differentiation of adenosine from other molecules 
with similar structure possible. 
2.3.5 In vitro MRI image change induced by adenosine 
An MRI image was acquired on a clinical MRI scanner. The image is shown in 
Figure 2.10. The left and middle samples are the contrast agent before and after addition 
of adenosine, respectively. As the T1 of the system increased after addition of adenosine, 
the sample showed a 25% contrast decrease with the presence of adenosine. The right 
sample contained only streptavidin and Gd-strand to simulate 100% released Gd-strand. 
As expected, the contrast of the left sample is brighter than the middle and right ones. 
The image shows that although T1 increased around 30% with the presence of adenosine, 
the contrast agents can give a significant contrast change on an MRI image. 
54 
 
 
Figure 2.10 in vitro MRI images of the adenosine aptamer-based contrast agent without 
(left) and with (middle) the presence of 5 mM adenosine. The right sample is the positive 
control to simulate 100% release of the Gd-strand. 
 
2.4 Conclusion, perspectives and future direction 
In conclusion, we designed and realized a smart T1-weighted MRI contrast agent 
based on DNAzyme and DNA aptamer. The 39E DNAzyme and adenosine aptamer were 
utilized in the contrast agent designs. The 39E DNAzyme-based contrast agent changed 
T1 only in the presence of uranyl cations. The adenosine aptamer-based contrast agent 
provided T1 increase in response to more than 0.5 mM adenosine. The T1 response was 
also observed in human serum. Both contrast agents have outstanding selectivity. The 
MRI image was acquired in vitro and a contrast change was observed with adenosine. 
The design of the contrast agent can be applied to other DNA or RNA aptamers and it 
opens a door to design smart MRI contrast agents rationally. However, the contrast agent 
is a “turn-off” sensor, which causes potential problems for in vivo application; the work 
presented is a first-step in this area. 
It is worthwhile to point out the direction of the research of the MRI contrast 
agents presented herein. First of all, streptavidin is expensive and not present in vivo. To 
decrease the cost, other proteins with high abundance is preferred. Thus, the next 
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generation of the contrast agents should avoid streptavidin. Proteins abundant in human 
body, such as albumin, should be used instead. Besides, the turn-on contrast response to 
the analytes is preferred because it excludes artifacts. Thus, research on turning on the 
contrast upon the presence of the analytes should be focused. 
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Chapter 3 Label-free aptamer-based fluorescent sensor by lighting 
up the fluorescence of malachite green  
 
In this chapter, a novel aptamer based-fluorescent sensor is presented. Different from 
previously reported designs, the DNA is not labeled with fluorophore and quencher in 
this work. This work is the basis for a published manuscript Xu, W.; Lu, Y. Anal. Chem. 
2010, 82, 574-578 
 
3.1 Introduction 
3.1.1 Malachite green and its aptamer 
Malachite green (MG) is a widely used dye in industry. The structure of the 
compound is presented in Figure 3.1. Because of its intense green color, MG has been 
used to dye silk, leather and paper. MG is considered a Class II Health Hazard as it can 
intercalate into the DNA duplex and introduce mutations in the DNA, leading to 
generation of tumors. Therefore, the  use of this dye is strictly monitored and regulated. 
 
Figure 3.1 Structure of malachite green 
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Although MG has an intense color, with an extinction coefficient as high as 105 
M-1cm-1 at 621 nm, it is not fluorescent. The deep color indicates that the molecule is able 
to absorb photons. However, the energy from the photons is not transferred to fluorescent 
emission. Instead, it is converted to heat because of the flexible σ-bonds.1,2 The quantum 
yield of MG was reported to be lower than 10-4.3 
In 1998, a RNA ligand (RNA aptamer) for malachite green was evolved by Grate 
et al.4,5 using SELEX.6-15 Their initial motivation was to fuse the MG binding site in 
cellular mRNA. The RNA-MG complex was then hydrolyzed selectively at the binding 
sites upon exposure to laser. Structural studies were then carried out to characterize the 
interaction between MG and its RNA ligand.16,17 An NMR study showed that MG was 
intercalated between a Watson-Crick base pair and a base quadruple. Both the stacking of 
aromatic rings and electrostatic interactions accounted for the binding affinity. The 
binding pocket is small and free vibration is restricted. The study indicated that the 
fluorescence of MG can be affected upon binding to its RNA aptamer. 
3.1.2 Light-up fluorescent sensor using MG 
As discussed above, MG is nearly non-fluorescent because of its flexible structure. 
Thus, if the structure is more rigid, it can be fluorescent – it can absorb photons because 
of its deep color and the energy relaxation is limited; photon emission then becomes the 
only option for energy release. The aptamer of MG was evidenced to make the MG 
molecule more rigid, thus, Tsien and co-workers systematically studied the fluorescence 
of triphenylmethane dyes, including MG, upon binding to their aptamers.3 It was 
discovered that the nearly non-fluorescent dyes became fluorescent. MG has an over 
2000-fold increase in quantum yield (from less than 0.0001 to 0.19). It was hypothesized 
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that the binding of the dye to its target limited its ability to vibrate and rotate at its 
previously flexible bonds. Thus, as the dye absorbed energy from excitation photons, it 
emitted it as fluorescence. 
The research opened a door for the design of fluorophore/quencher label-free 
sensors based on functional nucleic acids. The traditional fluorescent sensors regulate the 
distances between fluorophore and quencher so that the fluorescence can be changed in 
response to the analytes. These sensors require fluorophore/quencher labeling, which is 
costly and difficult to store and transport. Moreover, the quencher cannot completely 
remove the fluorescence of the fluorophore, leading to a relatively high background. If 
the binding of MG to its aptamer can be regulated by the presence of the analyte, a 
fluorescence change can then be monitored and the system can be applied as a sensor. 
Because the fluorescence is from MG, which is not fluorescent naturally, the background 
is expected to be lower than the labeled rivals. Avoiding fluorescent labeling significantly 
reduces the cost and difficulties in storage and transportation of the sensor. 
3.1.3 MG aptamer-based sensor development 
Aptamers have been converted into sensors with high sensitivity and 
selectivity.8,18-26 The fluorescent sensors27-35 are especially interesting because of the 
feasibility of quantification. However, most fluorescent aptamer-based sensors require 
fluorophore/quencher labeling, which is not convenient and cost effective as discussed 
above. Thus, we investigated methods to avoid the covalent labeling of fluorophore using 
MG and its aptamer as the platform. 
Label-free sensors were developed even before the MG aptamer was selected. It 
was realized by the fluorescence change of the fluorescent dyes upon intercalating into 
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double strand DNA. Although fluorophore labeling was avoided, most sensors have 
decreased fluorescent signal upon binding to the analytes. The sensitivity is thus 
significantly worsened compared to their labeled rivals.28,36-40 
The first successful trial using MG to realize turn-on sensing was reported by 
Stojanovic and co-workers.41,42 They conjugated the MG aptamers and analytes through 
an engineered “communication module.” The aptamer’s stem loop (shown in blue in 
Figure 3.2A) is critical for its affinity for MG, but when the aptamer binds its analyte its 
conformation changes. As shown in Figure 3.2B, the binding of the analyte (shown as a 
star) converts the dynamic, flexible structure of the aptamer into a rigid structure. The 
bases at the 3' and 5' termini hybridize in the presence of the analyte. The researchers 
combined the two aptamers shown in Figures 3.2A and 3.2B to produce the single 
structure shown in Figure 3.2C (the blue stems shown in Figures 3.2A and 3.2B are 
identical and serve as the connection point, or the “communication module”). As shown 
in Figure 3.2C, the blue stem in the combined structure will not hybridize in the absence 
of the analyte. Thus, the MG affinity is inhibited. Even with MG (shown as a grey circle) 
present in solution, no binding occurs and the MG remains non-fluorescent. When the 
analyte is added, the structure changes its conformation: the blue stem hybridizes, and its 
affinity for the MG aptamer (in red) is restored. Thus MG binds to its aptamer and 
increases in fluorescence. In their studies, three targets, adenosine triphosphate (ATP), 
theophylline, and flavin mononucleotide (FMN) as well as their aptamers were 
investigated. For the ATP sensor, a 4-5 fold maximum fluorescence increase was 
observed. An over 10-fold fluorescence increase was realized for the FMN sensor. 
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Figure 3.2 (A) The binding affinity of the aptamer is conformation-sensitive; (B) 
Binding-induced conformational change of the aptamer; (C) Label-free sensor based on 
MG aptamer 
 
The MG system was also utilized for DNA detection. Kolpashchikov pioneered 
this area by his work on nucleic acid recognition.43 As shown in Figure 3.3A, the MG 
aptamer is split into two subunits. Because the subunits interacted only weakly, they 
remained separate in solution. Thus, MG was free in solution and had low fluorescence. 
They designed the sensor by extending the subunits of the MG aptamer (shown in blue in 
Figure 3.3B). It now performed as a probe for the target DNA, since the target DNA 
provided extra affinity between the two subunits. Therefore, the two subunits hybridized 
together when MG and DNA was present. Meanwhile, as MG bound to the aptamer, its 
fluorescence increased. This system can detect single nucleotide mismatches, a gold-
standard for nucleic acid detection methods. Every single mismatch was tried, and 41 out 
of 42 mutations can be discriminated with an acceptable discrimination factor. 
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Figure 3.3 (A) Splitting of the MG aptamer and (B) DNA sensing based on MG aptamer 
The generalization of this methodology is still challenging. First, the 
communication module is the shared stem between the MG aptamer and the analyte 
aptamer. This stem does not necessarily exist for all aptamers. Second, structural 
information is important and even essential in the design. The engineering of the 
communication module is based on the knowledge of the conformation of the aptamer. 
Finally, the authors pointed out that optimizing the communication module was a trial-
and-error process that was time-and-money-consuming. 
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3.2 Generalized sensor design 
The design of the label-free aptamer fluorescent sensor is shown in Figure 3.4.44 
The sensor contains two nucleic acid strands. One is a chimeric conjugate of the 
adenosine DNA aptamer45 sequence (in blue) and MG RNA aptamer sequence (in red), 
called the “aptamer strand” in this chapter. The other is a DNA strand, called the 
“bridging strand” (in brown), that contain sequences complimentary to both the 
adenosine and MG aptamers. The sequence of the bridging strand is designed so that the 
aptamer and bridging strands form a stable complex in buffer at room temperature to 
prevent the MG aptamer strand from binding MG in the solution if there is no adenosine 
present. Under this condition, the MG remains free in solution and almost non-
fluorescent. In the presence of adenosine, however, the aptamer strand binds adenosine, 
leaving much less number of complimentary base pairs between the aptamer strand and 
bridging strand, which is less stable at room temperature, resulting in release of the 
bridging strand from the aptamer strand. As a consequence, the fluorescence of the MG is 
recovered.  
The sequence of the bridging strand is critical. However, there are some clues for 
the selection of the sequence. Firstly, the bridge strand inhibits the affinity of the MG 
aptamer to ensure low background when adenosine is not present. Secondly, the affinity 
of the adenosine aptamer to adenosine is not significantly affected by the bridging strand. 
Thus, the affinities should rank in the following order: bridge-MG aptamer > MG-MG 
aptamer; adenosine-adenosine aptamer > bridge-adenosine aptamer. The affinities of the 
aptamers are pre-determined by the nature of the aptamers; the sequence of the bridging 
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strand should make the affinities between the two strands meet the conditions presented 
above. 
 
Figure 3.4 Scheme showing the regulation of the fluorescence of malachite green by 
adenosine. Without adenosine, the affinity of the aptamer strand (in red and blue) is 
inhibited by the bridging strand (in brown). With adenosine, the bridging strand separates 
from the aptamer strand, which then binds malachite green, leading to an enhancement of 
fluorescence. 
 
 
3.3 Experimental 
3.3.1 Materials and DNA sequences 
Materials  Nucleic acids were purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA) with standard desalting. No further purification was performed. 
Malachite green and all other chemicals were purchased from Sigma-Aldrich. Buffers 
were prepared in Millipore water. 
Nucleic acids sequences The sequences of the nucleic acids in the research are 
presented in Figure 3.4. The bridging strands are named as Bridge M-N. M is the number 
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of the complimentary bases between the bridging strand and the MG aptamer; N is the 
number of the complimentary bases between the bridging strand and the adenosine 
aptamer. The length of the bridging strand is (M+N). 
3.3.2 Sensor preparations 
The sensor solution was prepared by dissolving the nucleic acid strands and 
malachite green in buffer. The solution was then heated to 80 ºC and cooled down to 
room temperature in about one hour to ensure that the system folds into the structure 
described in Figure 3.4. 
Because of the poor solubility of adenosine, the highest concentration of the stock 
solution that could be prepared was 50 mM. Thus, during the sensor preparation step, the 
dilution effect by the addition of adenosine was considered. In a typical procedure at the 
optimized conditions, 1.11 µM aptamer strand, 1.56 µM Bridge 9-6 and 0.67 µM MG 
were dissolved in 22 mM Tris buffer containing 5.56 mM NaCl, 155.6 mM KCl and 5.56 
mM MgCl2. After heating and cooling the solution as described above, 0.45 mL of the 
prepared solution was mixed with 0.05 mL of 10-times adenosine stock solution. After 30 
min, the fluorescence of the sample was measured and recorded. 
3.3.3 Fluorescence measurement 
Fluorescence experiments were carried out on a Fluromax-2 fluorimeter (HORIBA Jobin 
Yvon inc., Edison, NJ). Emission acquisition mode was used.  The excitation wavelength 
was 615 nm. The fluorescence at 650 nm was recorded. F/F0 was plotted as sensor signal. 
F is the fluorescence of MG after the addition of adenosine. During optimization 
procedure, F0 is the fluorescence of MG before addition of adenosine stock solution. For 
the sensor calibration curve acquisition, F0 is the fluorescence of the sensor solution with 
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addition of 0 mM adenosine (water). All the measurements were performed for 3 times 
and the standard deviation was plotted as the error bar. 
 
3.4 Results and discussions 
3.4.1 MG affinity to the extended aptamer strand 
MG was incubated with or without the aptamer strand in the buffer (20 mM Tris 
(pH 7.4), 145 mM NaCl and 5 mM MgCl2). The fluorescence of MG was measured in 
both conditions and presented in Figure 3.5. The purpose of the comparison is to ensure 
that the fluorescence enhancement by MG is not affected by the conjugation of the 
adenosine aptamer and that the selected buffer, which is a compromise of the selection 
buffers for both aptamers, is effective for the MG aptamer. An over 1000 fold 
fluorescence increase was observed, which indicated that the affinity of the MG aptamer 
was not affected significantly; it is reasonable to conclude that the affinity of the 
adenosine aptamer was not affected either.  
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Figure 3.5 The conjugate of aptamers of adenosine and MG has high affinity to MG in 
the selected buffer 
 
It is noted that the fluorescence increase was not as high as what was reported. 
This can be due to the conjugation of two aptamer sequences. However, with the decrease 
of the aptamer affinity, we still observed a thousand fold fluorescence increase, which is 
the up-limit of the signal-to-noise ratio for the future sensor. This upper-limit is already 
high than most labeled system; the quencher can only quench around 90% of the 
fluorescence from a fluorophore.  
3.4.2 Optimization of the bridging strand 
As mentioned above, the adenosine aptamer has been used to prove the concept of 
the structure switching sensors multiple times. Therefore, a significant amount of data is 
available about the properties of this aptamer. For example, when the first seven bases at 
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the 5 terminus hybridize with the antisense strand, the affinity of the adenosine aptamer 
is not significantly decreased. This provides valuable information for the sequence design 
of the bridging strand.  
In the present study, 6 base pairs at the adenosine aptamer end were selected to 
ensure the binding affinity between the aptamer strand and adenosine. It has been 
reported that 6 base pairs are effective in an adenosine aptamer structure switching.46 
The MG aptamer was less investigated than the adenosine aptamer; thus more 
attention was focused on the optimization of the number M (M was defined in section 
3.3.1). The bridge strand should prevent the MG aptamer from binding MG in the 
absence of adenosine to ensure a low background. At the same time, once adenosine 
binds to adenosine aptamer and starts structure switching, the hybridization between the 
MG aptamer part and the bridging DNA should not be stable at room temperature to 
ensure the release of it and binding of the aptamer strand to MG. We investigated the 
bridging strand that contains 6 bases that are complementary to adenosine aptamer and 
various numbers of bases that are complementary to MG aptamer (Bridge 6-6, 7-6, 8-6, 
9-6 and 10-6. See Figure 3.4 for the sequences).  
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Figure 3.6 Sequence optimization of the bridge strands. 9-6 has the highest fluorescence 
increase. 
 
During the optimization procedure, we tried to maximize the folds of the 
fluorescence increase upon the addition of 5 mM adenosine which was chosen as the 
signal output of the sensor. The kinetics of the reaction was monitored. We ensured that 
the equilibrium can be reached in less than 30 min. Upon addition of adenosine to the 
sensor solution, The folds of the fluorescence increase (F/F0) increases when the number 
of bridging strand base complementary to MG aptamer (M) increases from 6 to 9, and 
then deceases when the number is 10 (Figure 3.6). Based on these results we conclude 
Bridge 9-6 is the optimal for the sensing application.  
3.4.3 Sensor condition optimization 
After the optimization of the bridging strand, 6-fold fluorescence increase was 
observed if the optimized sequence was used. However, because of the complexity of the 
system, there are more parameters that can be optimized. This section will discuss the 
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optimization of the buffer conditions and the concentrations of the three nucleic acid 
strands. 
 
Buffer conditions optimization  Since there are two aptamers in the design, 
each with its own optimal buffer condition for performance, a common condition suitable 
for both aptamer functions should be found first. Although adenosine aptamer was in 
vitro selected in a 20 mM Tris-acetate buffer with pH 7.6, it has been reported that 
adenosine aptamer-based biosensors are effective in a range of pH between 7.4 and 8.3. 
In addition, the Na+ and Mg2+ concentrations can be varied from 100 mM to 300 mM and 
from 0 to 5 mM, respectively. Encouraged by these facts, we used the system developed 
by Li and co-workers to test the performance of adenosine aptamer in different buffers, 
and found that the sensing performance is similar at pH between 7.4 and 8.4 and 
concentrations of NaCl between 150 mM and 300 mM and MgCl2 between 2 mM and 5 
mM. 
After confirming the workable range of buffer conditions for adenosine aptamer, 
we next explored a common buffer condition that is also effective for MG aptamer. Since 
MG aptamer was selected in 10 mM Na-HEPES buffer at pH 7.4, together with 100 mM 
KCl and 5 mM NaCl, we decided to use 20 mM Tris (pH 7.4), 145 mM NaCl and 5 mM 
MgCl2 as a compromise between buffers for adenosine and MG aptamers.  
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Figure 3.7 Performance of the sensor with varied potassium concentration in the buffer. 
1 μM aptamer strand, bridge 6-5 and MG were used as the sensor. Besides KCl and NaCl, 5 
mM MgCl2 and 20 mM Tris (pH 7.4) were also present in buffer. 5 mM adenosine was 
added at t = 10 s and fluorescence versus time was recorded and plotted. 
 
Since the MG aptamer was selected in buffer containing potassium, we 
investigated whether replacing NaCl with KCl in the buffer may help to increase the 
performance of the sensor. The sensor performance was tested using Bridge 6-5 (Figure 
3.4) in buffers containing 20 mM Tris (pH 7.4), 5 mM MgCl2 and 145 mM of total 
monovalent metal ions, but with different ratios of Na+ and K+. Our results showed that 
variation of potassium concentration did not change the signal significantly (by around 
10%, Figure 3.7). Monovalent metal ions are necessary for the MG aptamer affinity 
because the DNA strand has to fold, during which the negative charge on the DNA 
backbone has to be neutralized. As K+ and Na+ has the similar ability to help DNA fold, 
variation of K+ concentration did not affect the sensor performance significantly. We 
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decided to use 20 mM Tris (pH 7.4), 5 mM MgCl2, 140 mM KCl and 5 mM NaCl as the 
optimized buffer to make it as close as possible to the buffer in which MG aptamer was 
selected. It is worthwhile to point that since two aptamers are used in this label-free 
system, each with its own optimized condition, the range of optimal conditions is much 
narrower than that of the labeled systems.  
 
Optimizations of the concentrations of the nucleic acid strands  Since there are 
three DNA species (the aptamer and bridging strands and MG) in the system, it offers a 
chance to optimize the ratio of the three species separately to increase the performance of 
the sensor. First, both DNA strands were kept 1 μM and MG concentration was varied. 
As presented in Figure 3.8A, MG = 0.6 μM has the best performance. We then kept the 
aptamer strand and MG concentrations to be 1 μM and 0.6 μM respectively and varied 
the concentration of the bridging strand (bridge 9-6). Based on the data in Figure 3.8B, 
1.0 μM and 1.4 µM of Bridge 9-6 have similar fluorescence fold increase in the presence 
of 5 mM adenosine (around 10% difference). We decided to choose 1.4 µM of Bridge 9-6 
to ensure the complete hybridization of the aptamer strand to the bridge strand. Therefore 
the optimal sensor design is for 1.4 μM Bridge 9-6 to be complementary to 1 μM aptamer 
strand while in the presence of 0.6 μM MG. 
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Figure 3.8 Optimization of the concentrations of MG (A) and the bridge strand 9-6 (B) 
3.4.4 Sensor response at the optimized conditions 
Under the optimal sensor design and buffer conditions, minimal fluorescence was 
observed in the absence of adenosine (black trace in Figure 3.9A). Upon addition of 5 
mM adenosine, however, a 12 fold increase in fluorescence was observed (red trace in 
Figure 3.9A), indicating that the binding of adenosine by the adenosine aptamer caused 
the release of the bridging strand, recovering the affinity of the MG aptamer, which then 
binds MG, resulting in a fluorescence increase.  
To quantify concentrations of adenosine based on the increase in MG 
fluorescence, we measured the saturated fluorescence upon addition of different 
concentrations of adenosine. The sensor solution concentration was diluted by 20% to 
what was described in the previous section in order to reduce the use of the materials. 
The results shown in Figure 3.9B indicate that the fluorescence of MG increases with an 
increasing concentration of adenosine, reaching ~12 fold fluorescence increase around 5 
mM adenosine. The inset of Figure 3.9B shows the region between 0 and 1 mM 
adenosine where a linear relationship was observed between adenosine concentration and 
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MG fluorescence. A detection limit of 20 μM at 90% confidence level was calculated, 
which is comparable with other adenosine aptamer-based sensors.  
3.4.5 Selectivity of the sensor 
To test the selectivity of the sensor, 5 mM cytidine or uridine, the highest 
concentration tested for adenosine, was added to the sensor solution and no fluorescence 
increase was observed (see Figure 3.9C). Our results suggest that the sensor is specific to 
adenosine. Guanidine was not used due to poor solubility. The extraordinary selectivity 
of the sensor is not surprising; the fluorescence increase is initiated by the binding of 
adenosine to the aptamer strand. Previous studies have shown that the adenosine aptamer 
used in this study is not responsive to cytidine or uridine; thus no fluorescence can be 
observed. It also proved that the fluorescence increase of MG is from adenosine instead 
of any other changes of the physical properties of the solution introduced by the addition 
of adenosine.  
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Figure 3.9 (A) Fluorescence enhancement of the optimized sensor upon the addition of 
adenosine; (B) the saturated fluorescence of malachite green with various concentrations of 
adenosine. The inset shows the fluorescence response at low concentrations of adenosine, 
and the red line shows a linear fitting of the data; (C) selectivity of the sensor toward other 
nucleosides. Cytidine and uridine did not increase the fluorescence of MG. 
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3.5 Conclusion, perspectives and future direction 
We have demonstrated coupling of adenosine aptamer strand with MG aptamer 
strand through a bridging strand in which the fluorescence of malachite green can be 
regulated by the presence of adenosine. This system has sensitivity and selectivity 
comparable to other adenosine sensor systems, with the benefit that labeling of the DNA 
with fluorophores is not required. More importantly, the design is based purely on DNA 
hybridizations and therefore can be more generally applied to other aptamers for the 
sensing of a broad range of analytes. 
There are two directions that the research can be further investigated. First of all, 
DNAzymes have been used to detect metal cations such Pb2+ and UO22+. The label-free 
sensor design can be adapted so that it can be used for metal cation sensing. This research 
will provide evidence for the generality of the design. Second, the RNA aptamer is not as 
stable as DNA. Thus, minimizing the RNA bases of the MG aptamer is important. 
Although the DNA strand with the same sequence as the MG aptamer does not bind to 
MG, mutation of the bases which are far away from the binding sites can significantly 
increase the stability of the aptamer strand without affecting the sensor performance. Or 
DNA aptamer selection can be carried on to evolve a new aptamer. 
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Chapter 4 Characterization of the interaction of Cu2+-dependent 
DNAzyme and Cu2+ 
 
This chapter focuses on the specific interaction between Cu sensitive DNAzyme, 
called Cuzyme, and Cu2+. Techniques including electron paramagnetic resonance (EPR), 
UV-Vis and circular dichroism were used in the characterization of this interaction. 
 
4.1 Introduction 
4.1.1 DNAzyme with Cu2+ as cofactor 
Among the nuclease-like DNAzymes, the Cu-dependent DNAzyme is unique.1-3 
Most DNAzymes with nuclease activity catalyze the cleavage of DNA/RNA chimeric 
strands,4-12 the cleavage site being an RNA base, such as 8-175 and 39E.11,12 The Cu-
dependent DNAzyme is the only DNAse-like DNAzyme that can cleave DNA.1-3 The 
substrate strand does not contain RNA bases. This DNAzyme was evolved and truncated 
by Breaker and co-workers in 1996.1-3  
 
Figure 4.1 Secondary structure of the DNAzyme (in blue) that can cleave another DNA 
strand (in black). The thick black arrow indicates the cleavage site. 
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During the selection, the DNA library was incubated with both Cu2+ and 
ascorbate at varying concentrations.1 The pool after seven rounds of selection showed 
robust nuclease activity and the pool after 8 rounds of selection was sequenced. Two 
classes of the Cu-dependent DNAzymes were selected in the original in vitro selection 
procedure carried out by the Breaker group, one of which required ascorbic acid even in 
the presence of Cu2+ (Class I). The other class (Class II) had activity even with the 
absence of ascorbate. More studies were conducted on Class II because of its relatively 
simple secondary structure and its ability to be truncated. 
This chapter focuses on studies of the truncated Class II DNAzyme. The 
secondary structure of the optimized Class II DNAzyme is shown in Figure 4.1. The 
enzyme strand (named Cuzyme herein) is blue, the substrate strand (named Cusub) is 
black and the cleavage site is red. There are three stems on the Cuzyme-Cusub complex. 
The 5' end stem forms a duplex with the 3’ end of Cusub (stem I); the 3’ end self folds 
and forms a triplex with the 5' end of Cusub (stem II). The stem in the middle is believed 
to be the binding position for Cu2+ (stem III). 
4.1.2  Progress on the characterization of the Cu2+-DNAzyme interaction 
There are limited reports on the characterization of the Cu2+-dependent DNAzyme, 
most of which is focused on biochemical methods of characterization.3 Mutational studies 
led to a proposed secondary structure of the DNAzyme.2 The original Class II DNAzyme 
was reduced to a 46mer without significant loss of activity. For example, it was 
discovered that the cytosine base at the 3' terminus of the 46mer was important to 
essential to activity. The triplex stem was proposed based on the result (Figure 4.1). 
Other mutational studies included varying the number of base pairings present in stem I 
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and mutating stem II. Maximum activity was achieved when stem I formed a duplex and 
stem II formed a triplex. The mutation studies provided solid evidence of the proposed 
secondary structure shown in Figure 4.1. 
Although the copper-dependent DNAzyme was selected in buffer at neutral pH in 
the presence of 1 M monovalent metal (K+ + Na+) and Cu2+ at varying concentrations, the 
DNAzyme showed some tolerance to changes in acidity and ion strength of the buffer. 
For instance, activity assays showed that the DNAzyme retained activity when the 
concentration of NaCl varied between 300 mM to 1 M. However, the DNAzyme is more 
sensitive to pH. Only ~50% activity was retained when the pH of the buffer varied from 7 
by 1 unit. Moreover, excessive Cu2+ can result in loss of DNAzyme activity. A 
significant drop in activity was reported when Cu2+ concentration was increased 100 µM 
Cu2+ and complete loss of activity occurred at 1 mM Cu2+. 
Previous mutational studies were helpful in elucidating the properties of the 
DNAzyme. However, the chemistry behind the catalysis has not yet been revealed by 
these studies. For example, the binding site and binding geometry of Cu2+ to the 
DNAzyme were still unknown. DNA has multiple binding sites for metal cations, such as 
the phosphate groups and bases. The number of Cu2+ ions capable of binding to each 
DNAzyme has not been reported either. Therefore, previous studies have opened the door 
for a deeper understanding of the interaction between the Cu2+-dependent DNAzyme and 
its metal cation cofactor, properties of which we address in our studies presented here. 
4.1.3 Cu sensor based on the Cuzyme 
Before the selection of Cuzyme, very few Cu sensors were available with high 
sensitivity13-24 and selectivity. Cu2+ is known to quench the fluorescence of dyes, leading 
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to low sensitivity. The selection of Cuzyme provided the opportunity to sense copper in 
solution. 
In 2007, Cuzyme was developed into a sensor for Cu2+ detection.25 The sensor is 
based on the Cuzyme-Cusub presented in Figure 4.1. The sensor design scheme was 
presented in Chapter 1. Under optimized conditions, a detection limit of 35 nM was 
reported. 
Ascorbate was added to accelerate the cleavage of Cusub so that the detection 
time can be shortened without loss of sensitivity. Although DNAzyme activity does not 
require the presence of ascorbate, the catalysis efficiency was significantly enhanced by 
its presence. 
It was well known that ascorbate can reduce Cu2+ to Cu+. Thus, it was suspected 
that the DNAzyme was sensitive to Cu+ too. It was discovered that the Cu2+ sensor also 
responded to Cu+, which indicated that Cu+ could also be detected. If ascorbate was not 
present, the signal of the sensor to Cu+ was higher than that of Cu2+ at the same 
concentration. This result indicated that the DNAzyme was more sensitive to Cu+ than 
Cu2+.25 However, the enzymatic activity of the DNAzyme with Cu+ has not been 
systematically studied. More mechanistic and structural information of the DNAzyme 
can be revealed by the study. 
4.1.4  Spectroscopic studies of the mechanism of the catalysis by DNAzymes 
It is possible to obtain important information of the interaction between 
DNAzymes and metal cations such as binding affinity through biochemical studies.26-30 
Mutational studies isolated the residue important for the copper binding. However, the 
majority of the detailed information of interactions cannot be revealed by biochemical 
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assays only, such as the ligands essential for metal cation binding, the metal binding 
geometry and the structure-related catalysis mechanism. 
Before the DNAzyme crystal structure was solved, spectroscopy was used to 
probe interactions that could not be determined by biochemical assays alone. For 
example, Fröster Resonance Energy Transfer (FRET) was used to study metal cation 
dependent folding of the DNAzyme.31-35 UV-Vis was used to directly observe binding of 
metal cations to the DNAzyme.36 Circular dichroism was used to probe global changes to 
DNA conformation.37-42 If the nucleic acids are spin-labeled, EPR is a powerful tool to 
study conformational changes as well.43-45 XAFS, although useful in characterizing 
metal-DNAzyme interactions, has not been widely applied because of the cost and 
difficulty of data interpretation.46  
Unfortunately, the majority of the divalent metal cations that are known to 
activate DNAzyme activity are spectroscopically silent, (e.g., Pb2+, Zn2+ and UO22+). In 
other words, these cations cannot be probed directly by spectroscopic means. Cu2+ is 
known to have EPR and UV-Vis signal. Thus, we aim at studying the Cu2+-DNAzyme 
interaction by spectroscopes.  
 
4.2 Experimental  
 4.2.1 EPR spectra acquisition 
DNA (0.5 mM, sequences in Figure 4.1) was dissolved in 50 mM HEPES (pH 7.0) 
buffer containing 1.5 M NaCl and 6% glycerin. CuSO4 was added to the solution at 
various concentrations, followed by flash freezing of the solution in liquid nitrogen. The 
samples were kept in liquid nitrogen until EPR spectra acquisition. 
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EPR spectra were acquired on a Varian E-line Century Series X-band CW EPR 
spectrometer at 30 K. The EPR parameters are summarized in Table 4.1. 
Table 4.1 Parameters of the EPR spectra acquisition 
Center 
(Gauss) 
Scan range 
(Gauss) 
Frequency 
(GHz) 
Scan 
number 
Power 
(mW) 
Modulation 
2800 2000 9 20 0.5 5 
 
4.2.2 Titrations by UV-Vis 
DNA (0.5 mM) was dissolved in 50 mM HEPES (pH 7.0) buffer containing 1.5 
M NaCl. Cu2+ was added slowly with stirring for at least 10 minutes, followed by the 
acquisition of the UV-Vis spectrum. 
UV-Vis spectra (400 nm-1400 nm) were acquired on a Varian 500 UV-Vis 
spectrometer with a scan rate of 300 nm per minute.  
4.2.3  Circular dichroism (CD) 
DNA (2.5 µM) was dissolved in 50 mM HEPES (pH 7.0) buffer containing 1.5 M 
NaCl. Metal cations were added slowly with stirring for at least 10 minutes, followed by 
spectrum acquisition. 
Buffer was used as the background. The samples were scanned from 220 nm to 
320 nm and each sample was averaged over 10 acquisitions.  
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4.3 Results and discussion 
4.3.1 EPR spectra interpretation 
To probe copper-dependent DNAzyme metal binding interactions, 1 equivalent of 
Cu2+ was added to 0.5 mM nucleic acids with varied sequences as well as the monomer 
of DNA – dNTP in buffer (50 mM HEPES, pH 7.0, 1.5 M NaCl). The nucleic acid 
sequences included the Cuzyme-Cusub complex, the 39E-39S complex (cis-form), the 
17E-17S complex (cis-form) and a mixture of dNTP (i.e., dATP, dCTP, dGTP and dTTP). 
The solutions were flash-frozen and subjected to EPR spectra acquisition. 
The normalized EPR spectra of the samples are plotted in Figure 4.2A. The 
spectra have similar shape and g values. This is different from what was expected. It was 
hypothesized that the interaction between Cu2+ and the Cuzyme-Cusub complex was 
specific; this spectrum should be different from those of Cu2+ and the control nucleic 
acids (17E and 39E systems and dNTP). Here, preliminary analysis through Peisach-
Blumberg plot indicates that Cu2+ binds to DNA molecules through their phosphate 
groups. Supporting evidence of this interaction comes from the observation that Cu2+ has 
strong affinity to phosphates. 
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Figure 4.2 Overlaid EPR spectra of Cu2+ with dNTP, 39E, 17E or Cuzyme (A); and a 
comparison of the EPR spectra of Cu2+ with 17E or Cuzyme (B) and 17E and 39E (C) 
However, several points are worth noting. First, the normalized signal strength of 
Cu2+ in Cuzyme-Cusub solution is stronger than the other control samples. As the 
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concentrations of Cu2+ in all samples were the same (0.5 mM), the signal difference can 
only be explained by the broadening of the signal. The EPR signal is broadened when the 
binding of Cu2+ to the ligand is flexible, which is common for Cu2+ in biological buffers 
such as Tris and HEPES. Signal broadening leads to a drop in the EPR signal intensity. 
Thus, the increased signal intensity of the Cuzyme-Cusub sample indicates that Cu2+ 
binds to Cuzyme-Cusub more strongly than the control DNA sequences and dNTP. The 
higher metal binding affinity can be from the specific interaction between the cofactor 
and the copper dependent DNAzyme. 
Slight shape differences of the EPR spectra were also observed. Figure 4.2B 
shows the overlay of the EPR spectra of Cu2+ in Cuzyme-Cusub solution with that of 
Cu2+ in 17E-17S solution. The three peaks, with g values at 2.5, 2.3 and 2.1, did not 
perfectly overlap. More significantly, a shoulder was observed at g=2.05 in the Cu2+-17E 
/17S sample. The shoulder was not significant in the Cuzyme-Cusub system. It is difficult 
to conclude that the binding modes of Cu2+ to DNA with different sequences are different 
since only a small difference in signal intensity indicated that the binding of Cu2+ to the 
Cuzyme-Cusub complex could be unique. It is noted that the spectra of Cu2+ with 
17E/17S and 39E/39S were almost identical in both shape and signal intensity (Figure 
4.2C), which can be interpreted as non-specific Cu2+ binding to DNA. 
4.3.2 EPR: Cu2+ Titration 
Since the EPR studies above did not give strong evidence of specific Cu2+ binding 
to the DNAzyme, a titration of Cu2+ into 0.5 mM Cuzyme-Cusub was performed. The 
purpose was to measure the binding affinity of the interaction and to determine the 
number of Cu2+ cations bound to each Cuzyme-Cusub complex. 
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Figure 4.3 EPR spectra of varying concentrations of Cu2+ in solution containing 0.5 
mM Cuzyme (A); and the plot of the integrated EPR signals versus Cu2+ concentration (B) 
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The EPR spectra of varying Cu2+ concentrations in solution with Cuzyme are 
presented in Figure 4.3A. No significant changes in spectral lineshape were observed 
with increasing concentrations of Cu2+. Although signal intensity increased with 
increasing Cu2+ concentrations, the changes were not linear. In order to present the trend 
more clearly, the double integral of the EPR signal versus the concentration of Cu2+ is 
plotted in Figure 4.3B.  
From Figure 4.3B, a linear relation was observed when the concentration of Cu2+ 
was between 0 and 1 mM; when the Cu2+ concentration exceeded 1 mM, the signal 
increase was not linear. The signal saturation is interesting because it indicated that there 
were two binding modes. When the Cu2+ concentration is lower than 1 mM, Cu2+ binds to 
DNA in mode 1. Due to a limited number of the binding sites in this mode, when the 
concentration of Cu2+ exceeds 1 mM, Cu2+ binds to the DNAzyme in an alternative mode, 
leading to signal saturation. 
It is possible to calculate the number of binding sites for mode 1. The red traces in 
Figure 4.3B are the linear fitting of data points at Cu2+ concentrations lower than and 
higher than ~1 mM. The two fits intersect at 0.95 mM, indicating that ~2 equivalents of 
Cu2+ can bind to the DNAzyme (0.5 mM) in mode 1. This number provides evidence that 
mode 1 binding of Cu2+ is specific and that this may be the species responsible for 
enzymatic activity. 
4.3.3 Circular dichroism (CD) characterization of the metal-DNAzyme 
interaction 
EPR studies showed that the modes of specific and non-specific metal binding 
may involve similar ligands and binding geometry. Although these modes are 
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distinguishable, no other information can be acquired without advanced EPR techniques 
such as 2D-EPR. Thus, other spectroscopic techniques including CD were used to 
characterize the interaction between the copper sensitive Cuzyme and Cu2+. 
 
Figure 4.4 Circular dichroism spectra of Cuzyme (A, B, C) and control samples of 
double stranded DNA (see details in texts; D, E, F) with various concentrations of Cu2+. 
Intensities of the spectra versus Cu2+ concentrations were plotted in B and E. The difference 
of the spectra in the presence or absence of 4 equivalents Cu2+ were plotted in C and F. 
 
Circular dichroism was used to characterize the secondary structure change of the 
DNAzyme induced by Cu2+ binding. Cuzyme-Cusub and Cusub-Antisub (antisub refers 
to the antisense sequence of Cusub) were dissolved in buffer (2.5 µM) in the absence or 
presence of Cu2+. The spectra were plotted in Figure 4.4A (Cuzyme-Cusub system) and 
Figure 4.4D (Cusub-Antisub system). There was no significant change in the shape of the 
spectra. It is not surprising because CD monitors the conformation of DNA; DNA folding 
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important to enzymatic activity. This denaturing is unique, which was not observed in the 
control system.  
Further investigation was carried out by addition of 4 equivalents of various metal 
cations into a solution of Cuzyme-Cusub. The CD spectra was acquired and plotted in 
Figure 4.5A. Slight intensity change was only observed when Cu2+ was added. The 
corresponding difference CD spectra are plotted in Figure 4.6B. It can be observed that 
Zn2+, Cd2+ and Hg2+ did not introduce any signal change. Pb2+ led to changes in CD 
intensity which was only half of the change observed by introduction of Cu2+. The result 
emphasizes the specificity that Cuzyme has for Cu2+. 
4.3.4 Proposed mechanism 
The metalloenzyme model suggests that the metal cation is the active site for 
catalysis, and that the protein/DNA ligand provides the necessary binding mode for 
activity. However, It has been discovered that folding plays an important role in the 
reaction catalyzed by DNAzymes. For example, both FRET and single molecule FRET 
indicated that the cleavage reaction catalyzed by 8-17 with the presence of Zn2+ includes 
two steps, the conformational change resulting from the addition of Zn2+ (folding) and 
that during cleavage. In addition to folding, the activity of the DNAzymes, such as 10-23 
and 8-17, can be activated by monovalent metal cations.38 Based on these discoveries, it 
was proposed that the DNAzyme catalyzed reaction is conformation-change-based. The 
most specific metal cation cofactor has the highest folding efficiency (and thus highest 
activity), which explains the selectivity of the DNAzyme.  
The Cu-dependent DNAzyme is hypothesized to be conformation sensitive. 
Cuzyme can switch to the active conformation upon binding Cu2+, as Cu2+ can induce 
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DNAzyme folding through binding to the DNA phosphates. This may be the reason why 
EPR did not show very different spectral differences upon Cu2+ addition to Cuzyme in 
comparison to the control DNA. Different from the control DNA, Cuzyme takes a 
specific conformational change, which accounts for the catalytic activity. This 
conformational change was probed by CD as the “denaturing” of the enzyme-substrate 
complex. 
 4.3.5 UV-Vis Cu2+ titration 
As Cu (II) has UV-Vis-NIR absorption, we hoped to use UV-Vis spectroscopy to 
study the interaction between the Cuzyme and Cu2+. UV-Vis has been widely used to 
study the binding of Cu2+ to biomolecule ligands. Binding affinities can also be measured 
through titration. Thus, we titrated CuSO4 into the Cuzyme system and used dsDNA 
(double stranded DNA) as a control system. As shown in Figure 4.6, we observed very 
similar Vis-NIR spectra. There are three major peaks on the spectra at 700 nm, 950 nm 
and 1150 nm. The peak at 1150 nm is in the IR region, which is close to the water 
absorption band. This peak is relatively weak, and of the same intensity as background 
peaks so we did not use it for analysis. 
Signal saturation was not observed in our studies, indicating that there was only 
one mode of binding, or the binding modes cannot be distinguished by this technique. 
The lack of binding saturation did not allow for the calculation of a binding affinity. The 
origins of the peaks are not clear. It is probably due to the binding of Cu2+ to the 
phosphates. It solidifies the mechanism proposed above that Cu binds to phosphate 
groups on the DNAzyme, leading to a conformational change that accounts for the 
cleavage of the substrate strand. 
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A more rigorous way to probe conformational changes is to use FRET. It is 
predicted that if a DNAzyme is internally labeled with a fluorescent donor and acceptor, 
the FRET efficiency would correlate to Cu2+ concentration. Single molecule FRET 
experiments can even reveal more information on the hypothesized conformation change 
induced by Cu2+. Another direction that can be considered is that 2D-EPR. Thus it is 
possible to obtain more specific information about the binding mode. Moreover, if the 
DNAzyme is spin labeled, it is even possible to know the residue that responsible for 
Cu2+ binding.  
Perhaps the most complete information of the Cu2+-Cuzyme interaction will be 
achieved by solving either the NMR or crystal structure of the complex. Spectroscopy is 
a powerful tool, but it is difficult to obtain a complete image of the metal-DNAzyme 
interaction through the use of any one spectroscopic technique. This problem can 
potentially be solved by the acquisition of a three dimensional structure of the copper 
bound Cuzyme system, which may also shed light on other metal dependent DNAzyme 
systems. 
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Chapter 5 Cooperativity of the 8-17 DNAzyme 
 
In this chapter, the responses of a fluorescent sensor based on the 8-17 DNAzyme 
in the presence of two metal cations are discussed. During the course of data analysis, 
information about the interaction between the 8-17 DNAzyme and metal cations was 
revealed.  
 
5.1 Introduction  
5.1.1 8-17 DNAzymes 
The specific interaction of metal cations and nucleic acids has been of interest to 
researchers for decades.1-8 This field has experienced an increased interest after the 
discovery of ribozymes9-11 and DNAzymes,12 the corresponding RNA and DNA catalytic 
nucleic acids that require metal cations for their enzymatic activity.13-25 It has been 
hypothesized and accepted that the metal cations bind to ribozymes or DNAzymes in the 
same way as metalloproteins.6 However, the binding mode of metals in metalloproteins 
can be probed by physical techniques. Very few cases of the biophysical studies of the 
DNAzyme/ribozyme-metal interaction have been reported. 
The ‘8-17’ DNAzymes  are a class  of catalytic DNA molecules  that catalyze the 
cleavage of chimeric DNA/RNA substrates, and  have been isolated in   multiple research 
groups under differing selection conditions.26-33 The DNAzyme-substrate complex 
contains three parts – two double stranded “arms” and a loop (Figure 1.2). The loop is 
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believed to be the binding site of the metal cofactor; however, direct evidence for the 
hypothesis has not been reported.  
The catalytic activity of 8-17 requires the divalent metal ions as the cofactor. The 
activity of the cofactor follows the order: Pb2+>> Zn2+>>Cd2+>Mg2+≈ Ca2+.34 Because the 
8-17 DNAzyme has much higher activity in the presence of Pb2+ than any other metal 
ions, it was converted to biosensors for highly selective detection of Pb2+. 17E DNAzyme 
falls into the 8-17 category and it has been converted into various biosensors for Pb2+ 
detection with high sensitivity and specificity. However, a systematic study of the sensor 
response to Pb2+ in the presence of other metal cations has not been reported thus far.  
5.1.2 Model for the kinetics of the 8-17 catalyzed reactions 
Both biochemical and biophysical characterizations supported the hypothesis that 
the 8-17 DNAzyme is a metalloenzyme.34 Similar to other metalloenzymes, the catalytic 
kinetics follows the Michaelis-Menton equation. The fluorescent resonance energy 
transfer (FRET) studies show that the catalysis is a one-step or two-step procedure. Pb2+ 
does not change the conformation of the DNAzyme-substrate complex and the cleavage 
happens upon binding of Pb2+. However, other metal ions, such as Zn2+, change the 
confirmation of the DNA complex, followed by the cleavage of the substrate.35-37 Single 
molecular FRET studies were consistent with this observation.38 Besides divalent metal 
ions, monovalent metal ions such as Li+ and NH4+ were able to fold DNAzyme-substrate 
complex, followed by cleavage of the substrate. During the folding process, Z-DNA 
formation at the hypothesized metal binding region was even observed.39 Because of the 
diversity of the metal cation cofactors and their different folding effect, it is difficult to 
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hypothesize that the binding sites and binding geometries are the same for all the cations 
because of the diversity of the cation co-factors that can activate the DNAzyme.  
5.1.3 8-17-based fluorescent sensors 
17E DNAzyme which belongs to the 8-17 DNAzymes has been developed into 
biosensors for Pb2+ detection.40,41 As the catalytic activity of 17E is much more sensitive 
to Pb2+ than other divalent metal cations, the sensors were reported to have high 
selectivity. The sensitivity of the sensors varies with the signal transduction technologies. 
The fluorescence based on 17E has sensitivity as low as 10 nM, which is 50 times lower 
than the EPA defined lead toxic level. 
The recovery of the fluorescence includes two steps – the substrate cleavage and 
the dissociation of the product. The first step is believed to be the rate-limiting step. 
Although the sensor is usually used for Pb2+ detection, it is a powerful tool to study the 
kinetics of the DNAzyme because of less time consumption compared to kinetic assays 
based on gel electrophoresis. In this chapter, 8-17-based Pb2+ sensor was used to study 
the kinetics of the 8-17 DNAzyme in the presence of both Pb2+ and another metal cation, 
namely Zn2+, Cd2+ or Mg2+.  
 
5.2 Experimental 
5.2.1 DNA and chemicals 
Nucleic acids were purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA) with HPLC purification. Other chemicals were purchased from Sigma-
Aldrich. Buffers were prepared in Millipore water. 
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The sequences of the DNAs are presented in Table 5.1 
Table 5.1 DNA sequences of the 8-17-based sensor 
17S 5′-FAM-ACTCACTAT rA GGAAGAGATG-dabcyl 
17E 5′-CATCTCTTCTCCGAGCCGGTCGAAATAGTGAGT-BHQ1 
 
5.2.2 Fluorescence measurement and data analysis 
Both 17E and 17S were dissolved in buffer of 50 mM HEPES-Na (pH 7.0) with a 
concentration of 30 nM. The sensor solution was heated to 80 °C and cooled to ambient 
temperature in one hour to ensure complete hybridization.  
Fluorescence experiments were carried out on a Fluromax-2 fluorimeter 
(HORIBA Jobin Yvon inc., Edison, NJ). Kinetics mode was used in the data acquisition.  
The fluorophore was excited at 495 nm and the reslting emission at 520 nm was recorded. 
After the addition of metal cations, the emission was recorded for six times with various 
time intervals based on which the initial fluorescence rate was calculated. The 
fluorescence versus time was plotted and linearly fitted. The slope is defined as the initial 
rate (dF/dt). The time intervals were between 1 s and 10 s to ensure 1) the fluorescence is 
not saturated and 2) noise is minimized. All the measurements were performed 3 times 
and their average was plotted. 
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5.3 Results and discussions 
8-17-based sensors were developed for detection of Pb2+ in drinking water and 
paint, when Zn2+ interference was observed during detection (unpublished data). As 
reported before,41 the 8-17-based sensor is around a hundred times more sensitive to Pb2+ 
than to Zn2+. It was reported that if the concentration of Zn2+ is close or lower than Pb2+, 
the false positive signal would be around 1%. However, practically, a much higher false 
positive signal than what was expected was observed when both Pb2+ and Zn2+ were 
present (unpublished data, and the systematic results are shown in the next section). It 
was realized that this phenomenon was not only practically important, but also of 
scientific interest. Thus, we aimed at performing a systematic study of the response of the 
8-17-based sensors towards the co-existence of Pb2+ and other divalent metal cations. 
Zn2+, Cd2+ and Mg2+ were chosen for this study because their range of responses towards 
the 8-17 varied considerably in terms of absolute concentrations for activity of the 
DNAzyme.. 
5.3.1 Fluorescence responses of the 8-17-based sensor towards the 
coexistence of Pb and Zn 
First, we measured the fluorescence increase with various concentrations of the 
metal cations. As shown in Figure 5.1A, the sensor has linear response versus the Pb2+ 
concentration when it is between 0-4 µM. The overall signal however is not linear, and 
when the concentration is higher than 8 µM, saturation of the response is observed. 
Figure 5.1B shows that the linear range of the sensor towards the presence of Zn2+ is 0 to 
150 µM. The signal reaches saturation when the concentration of Zn2+ is higher than 300 
µM. To fully characterize the performance of the sensor with co-existence of Pb2+ and 
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Zn2+, we chose the Pb2+ and Zn2+ concentrations to be 0.4, 2, 5, 10 µM and 20, 100, 200, 
400 µM, respectively. Four concentrations were chosen so as to represent the lower linear 
range, higher linear range, non-linear range and saturation range. Thus, our first trial was 
to measure the sensor response towards the presence of both Zn2+ and Pb2+ with the 
combinations of the concentrations mentioned above; the results are presented in Figure 
5.1C. It was observed that presence of Zn2+ enhanced the signal from 0.4 or 2 µM Pb2+. 
This is not surprising because it was reported that Zn2+ responds to the 8-17-based 
sensor.41 However, it may also be noticed that at high concentration of Pb2+ and Zn2+ (for 
instance, the Pb2+ and Zn2+ concentrations are 10 and 400 µM respectively), Zn2+ did not 
interfere the Pb2+ sensing. This is due to the saturation of the signal.  
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Figure 5.1 Initial rates of the fluorescence increase of the 8-17 sensor in the presence of Pb2+ 
(A), Zn2+ (B) and both (C). Calculated cooperativity was plotted in (D). 
 
In order to better understand and analyze the data, we define: 
Cooperativity = S (Pb2++Zn2+)/[S(Pb2+)+S(Zn2+)] where S(Pb2++Zn2+), S(Pb2+)and S(Zn2+) 
mean the initial fluorescence increase rates of the 8-17-based sensor in the presence of 
both Pb2+ and Zn2+, Pb2+ and Zn2+ only, respectively. 
If the sensor has linear response towards different metal ions, we expect the 
cooperativity to be 1. Cooperativity versus concentrations of metal cations is plotted in 
Figure 5.1D. Consistent with what we observed before, when both Pb2+ and Zn2+ 
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concentrations fall in the linear range, we observed a cooperativity effect wherein, the 
combined signal was higher than 1, which suggested that the sensor exhibited non-linear 
performance upon coexistence of two metal cations. However, this phenomenon was not 
observed when the Pb2+ concentrations were higher than 4 µM, which was ascribed to the 
signal saturation. In order to investigate the cooperativity (>1) exhibited at the lower 
linear range concentrations of both metal ions, we decided to lower their concentrations 
further.  
 
Figure 5.2 Initial rate of fluorescence increase of the 8-17 sensor (A) and calculated 
cooperativity (B) with both Pb2+ and Zn2+. 
 
We chose concentrations at the lower linear range from 0.2, 0.5, 1, 2 µM and 10, 
20, 50, 100 µM for Pb2+ and Zn2+ respectively. The signal responses of the 8-17-based 
sensor towards the presence of the mixture of Pb2+ and Zn2+ with various concentrations 
are plotted in Figure 5.2A. We observed that the signal increased significantly in the 
presence of Zn2+ saturated the sensor signal when the Pb2+ concentration was kept at a 
constant value. Cooperativity was calculated and plotted in Figure 5.2B. We observed the 
cooperativity reached as high as 3.6 when Pb2+ and Zn2+ concentrations were 0.2 and 20 
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µM. The cooperativity decreased with the increase of the concentrations of both metal 
cations. From Figure 5.2A, we conclude this decrease is still due to signal saturation.  
5.3.2 Fluorescence responses of the 8-17-based sensor towards the 
coexistence of Pb and other metal cations 
Since this phenomenon was both interesting and encouraging, we also wondered 
about the generality in the presence of other metal ions. Thus, we measured the 8-17 
sensor response towards the co-existences of Pb2+/Cd2+ and Pb2+/Mg2+. Cd2+ was chosen 
because it has the similar electronic structure with Zn2+. Mg2+ was chosen due to its high 
abundance in water. As Cd2+ has similar properties as Zn2+, but with lower 8-17 activity, 
we chose the concentrations to be 50, 100, 200 and 500 µM. We chose the concentrations 
of Mg2+ close to the environmental level (up to mM level), which were 0.5, 1, 2 and 5 
mM. The signal and cooperativity of the sensor to the metal cations mixture are plotted in 
Figure 5.3. 
Interestingly, the cooperativity studies with Cd2+ indicated that it inhibited the 
combined signal. When the concentration of Pb2+ was constant, the signal decreased with 
the increase of Cd2+. The signal increased with an increased concentration of Pb2+ when 
the Cd2+ concentration is constant. We also observed a decreased cooperativity with 
increased concentrations of both cations. The interference of Mg2+ to Pb2+ sensing is 
more complicated. With 0.5 mM Mg2+, the Pb2+ signal was enhanced and the 
cooperativity was higher than 1. At this concentration, Mg2+ performed like Zn2+. With 
higher concentration, Mg2+ inhibits the 17E activity, with cooperativity lower than 1. 
Mg2+ shares similarity to Cd2+ at high concentrations (higher than 1 mM). 
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Figure 5.3 Initial rate of fluorescence increase of the 8-17 sensor (A and C) and 
calculated cooperativity (B and D) with Pb2+/Cd2+ (A and B) and Pb2+/Mg2+ (C and D) 
 
5.3.3 Theoretical investigation 
We believe that cooperativities other than ‘1’ are of scientific interest because it 
sheds light on the cation-DNAzyme interaction. Based on the idea that 8-17 is a 
metalloenzyme as our starting point and considering the simplest case wherein, the 
responses of the 8-17 toward Zn2+ and Pb2+ are independent, we assume that: 
 (1) DNAzyme-substrate complex (ES) binds metal cation cofactor (M). The ES-M 
complex accounts for the cleavage of the substrate 
(2) Steady-state assumption is valid and used to simplify the mathematics 
110 
 
 (3) The DNAzyme individually binds to each of the metal cation; the interaction of the 
DNAzyme two-metal species is ignored.  
Thus, we have the processes described in Figure 5.4.  
 
Figure 5.4 Kinetic model of the 8-17 catalyzed cleavage of the substrate strand 
 
Steady-state assumption is also utilized herein to simplify the calculation. The 
metal-DNA complexes thus have the constant concentrations. We thus have the following 
equations. 
ௗሾாௌି௉௕ሿ
ௗ௧
ൌ ݇ଵሾܧܵሿሾܾܲଶାሿ െ ݇ିଵሾܧܵ െ ܾܲሿ െ ݇ଶሾܧܵ െ ܾܲሿ ൌ 0   (5.1) 
ௗሾாௌି௓௡ሿ
ௗ௧
ൌ ݇ଵ′ሾܧܵሿሾܼ݊ଶାሿ െ ݇ିଵ′ሾܧܵ െ ܼ݊ሿ െ ݇ଶ′ሾܧܵ െ ܼ݊ሿ ൌ 0   (5.2) 
At the initial stage, we ignore the cleaved product, thus we have the following 
equation 
ܧ଴ ൌ ሾܧܵሿ ൅ ሾܧܵ െ ܾܲሿ ൅ ሾܧܵ െ ܼ݊ሿ      (5.3) 
Through equations 5.1-5.3, we can calculate the concentrations of both ES-Pb and 
ES-Zn complexes, which are presented in equations 5.4-5.5. 
ሾܧܵ െ ܾܲሿ ൌ ாబሾ௉௕
మశሿ௞′ಾ
௞ಾ௞′ಾା௞ಾሾ௓௡మశሿା௞′ಾሾ௉௕మశሿ
      (5.4) 
ሾܧܵ െ ܼ݊ሿ ൌ ாబሾ௓௡
మశሿ௞ಾ
௞ಾ௞′ಾା௞ಾሾ௓௡మశሿା௞′ಾሾ௉௕మశሿ
      (5.5) 
In the equations, kM and k’M are the apparent dissociation constants of DNA-
metal complex. They are defined by equation 5.6. 
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݇ெ ൌ
௞షభା௞మ
௞భ
          (5.6) 
Thus, we can calculate the initial reaction rate. 
ݒ଴ ൌ
ௗሾ௉௥௢ௗ௨௖௧ሿ
ௗ௧
ൌ ݇ଶሾܧܵ െ ܾܲሿ ൅ ݇′ଶሾܧܵ െ ܼ݊ሿ ൌ
ாబሺହ.ൣ௉௕మశ൧௞′ಾ௞మାாబൣ௓௡మశ൧௞ಾ௞′మሻ
௞ಾ௞′ಾା௞ಾሾ௓௡మశሿା௞′ಾሾ௉௕మశሿ
 (5.7) 
With the same assumption, we can calculate the initial rate for the cleavage of the 
substrate catalyzed by the DNAzyme strand and Pb2+ or Zn2+ only. They are presented in 
Equations 5.8-5.9. 
ݒ଴ሺܾܲሻ ൌ
ாబൣ௉௕మశ൧௞మ
௞ಾାሾ௉௕మశሿ
         (5.8) 
ݒ଴ሺܼ݊ሻ ൌ
ாబൣ௓௡మశ൧௞′మ
௞′ಾାሾ௓௡మశሿ
         (5.9) 
Mathematically, v0(Pb) or v0(Zn) < v0 < v0(Pb) + v0(Zn), or the cooperativity is 
lower than 1. This is not what we observed, which evidences that our assumptions are 
incorrect. As assumptions 1 and 2 have been widely accepted, we believe that the 
inconsistency between our observation and derivation is because assumption 3 is wrong. 
5.3.4 Proposal of the new binding model 
To interpret the data, we propose a new intermediate [DNAzyme-Zn-Pb]. This 
species has faster reaction rate and accounts for the cooperativity higher than 1. Our 
previous studies indicated that Zn2+ introduced a global folding of the DNAzyme-
substrate complex while Pb2+ does not introduce an observable folding by FRET. The 
result evidenced that Pb2+ and Zn2+ have different binding mode and binding site. Thus, it 
is possible for both of them to bind the DNA complex and have a higher reaction rate. 
Our proposal is presented in Figure 5.5. 
The inhibition of cleavage reaction by Cd2+ can be due to two possible reasons. 
Cd2+ or Mg2+ has the same binding site as Pb2+, and [DNAzyme-Cd] complex is not as 
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reactive as [DNAzyme-Pb] intermediate. Another possibility is that both the metal 
species bind to the DNAzyme complex. The inhibition is because of the low reactivity of 
[DNAzyme-Pb-M] intermediate. We believe the latter is closer to the reality. If the 
former was true, there would be two intermediates present, [DNAzyme-Cd] and 
[DNAzyme-Pb]. Thus, the reaction rate should be between the rates with the presence of 
only Pb2+ and Cd2+. This was not observed, making us believe the existence of 
[DNAzyme-Pb-Cd] intermediate. Mg2+ accelerates cleavage with low concentration and 
inhibits the reaction at high concentration. We hypothesize that the folding of the DNA 
complex is different with different concentrations, which makes the reactivity of 
[DNAzyme-Pb-Mg] different. 
 
Figure 5.5 Proposed interaction of the metal cations and 8-17 DNAzyme. Red triangle 
stands for Pb2+ and green ball stands for Zn2+. 
 
5.4 Conclusion, perspectives and future direction 
We systematically studied the signal responses of the 8-17-based sensor towards 
the co-existence of Pb2+ and other divalent metal cations. It was observed that Zn2+ 
accelerates the cleavage reaction and Cd2+ inhibits the reaction. Mg2+ accelerates the 
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reaction at low concentration and inhibits the reaction at high concentration. We initially 
assumed that the DNAzyme-substrate complex bound to each to metal ion and formed to 
distinct DNAzyme-metal ion intermediates; however, this assumption was different from 
our observations.  
We therefore propose a new intermediate [DNAzyme-Pb-M], which accounts for 
the acceleration or inhibition of the reaction. The hypothesis can be proved by careful 
FRET experiments. The study on the one hand presents challenges for application of the 
8-17-based sensor in diverse metal ion environments, and on the other hand presents a 
direction for interpretation of obtained results. 
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Chapter 6 Aptamer functionalized liposomes for targeted drug 
delivery 
This work has been published in Angewandte Chemie. (Cao, Z.; Tong, R.; Mishra, A.; Xu, 
W.; Wong, G. C. L.; Cheng, J.; Lu, Y. Angew. Chem. Int. Ed. 2009, 48, 6494-6498). 
 
6.1  Introduction 
 
6.1.1 Brief introduction to liposomes 
A liposome is a construct that mimics cell membranes. The word liposme comes from the 
Greek “lipo” meaning “fat” and “soma” meaning “body.” Today, the term liposome 
refers to an artificial vesicle composed of a phospholipid bilayer. A typical liposome is 
shown in Figure 6.1. 
As shown in Figure 6.1, liposome is a hollow spherical structure composed of a 
phospholipid bilayer. The phospholipid bilayer assembles through hydrophobic 
interactions. The alkyl chains of the lipids are hydrophobic and thus in an aqueous 
environment are energetically driven to associate with one another inside the bilayer 
while the hydrophilic phosphates expose themselves to direct contact with the aqueous 
solution. 
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Figure 6.1 Liposome structure. Liposomes have hollow spherical construct 
composed of phospholipids. The phospholipids have hydrophilic phosphate and 
hydrophobic carbon chains. 
 
Liposomes are not stable. They are sensitive to heat, osmotic pressure, and solution 
density changes. For example, if the osmotic pressure inside and outside the liposome is 
not balanced, this can cause the liposome’s components to rearrange, leading to the 
leakage of the species encapsulated inside, or even destroy the liposome’s structure. 
Density changes lead to the ascendance or subsidence of the liposomes, which 
significantly destabilize the liposomes. Moreover, liposomes are sensitive to chemicals 
that interact with lipids. For instance, it was discovered that phospholipid 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) binds mercury. The liposomes composed of 
DOPE can be destroyed by Hg2+ because of the surface energy change induced by the 
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binding event. The binding leads to the reassembly of the bilayer structure to reach the 
lowest energy.1,2  
6.1.2 Liposomes in drug delivery 
Liposomes are of interest to biologists and physicians because they have been widely 
used in the delivery and controlled release of drugs. Liposomes can encapsulate drug 
solutions and effectively protect the encapsulated drug from hazardous conditions such as 
the presence of acid and enzymes encountered during the drug delivery process. 
Liposomes are expected to release the drug into cells. There are three mechanisms by 
which unfunctionalized liposomes release encapsulated drugs. First, because of the 
amphipathic nature of the phospholipids which compose both liposomes and cell 
membranes, these structures can fuse with cells and deliver the encapsulated drugs. 
Second, when the phospholipids of the liposomes fuse with a cell membrane, the 
liposome becomes part of the cell, releasing the drug into the cell. Finally, if some 
portion of the liposome survives intact inside the cell, organelles such as lysosomes can 
open them, releasing their encapsulated drug.3 
After forty years of development,4 liposomes have been approved by the U.S. Food and 
Drug Administration for clinical applications.5 However, targeted drug delivery using 
liposomes has not yet been widely applied, and there is room for improvement in 
liposome technology. The strategy to increase the efficacy of liposome-based delivery 
focuses on enhancing their permeation and retention (EPR),6,7 which is a passive strategy. 
The most important challenge in this field is side effects due to non-targeted drug 
delivery.8,9 Previous studies have shown that cisplatin,10,11 an inorganic anti-tumor drug 
with significant cytotoxicity,12 when encapsulated in liposomes, had poor-to-moderate 
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efficacy.13,14 The problem can only be solved by functionalizing the liposome to bring 
about targeted drug delivery.15 
Antibodies dominate the field of targeted drug delivery.12,16-19 They are of practical 
significance in the delivery of drugs that have severe side effects. As mentioned above, 
cisplatin is a platinum-based complex. It was discovered that cisplatin reacts with DNA 
in cells, leading to the dysfunction of genomic material.10,11 Its function is nonspecific, 
being equally toxic to cancerous and non-cancerous cells. Therefore, to specifically target 
cisplatin to cancerous cells, it has been functionalized by antibodies17-19 which recognize 
the receptors on the surface of tumor cells, to enhance the uptake of the medicine by the 
tumor and to minimize the side effects. However, challenges exist.20 First, antibodies are 
difficult to control; they have poor site specificity and varied affinity. Second, antibodies 
are immunogenic,21 which requires extra steps before the drug delivery. And finally, 
antibodies are produced in biological systems, which cause cost issues when the system is 
scaled up. 
6.1.3 Aptamers that target tumor cells 
One alternative to antibodies is aptamers. Aptamers22-26 have promising applications in 
cancer biology, since aptamers that recognize cancer-related proteins including PDGF, 
VEGF, HER3, NFkB, and PMSA have been found.27 Although they have not yet been 
applied in clinics, the aptamers could perform important roles in the treatment of 
cancer.28-43 
Aptamers can find more applications in cancer biology because of a method developed 
by Tan and co-workers called cell-SELEX,27 a SELEX process that uses cells as the 
selection target. During the selection process, the aptamers are selected to bind to one of 
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the components of the cell membrane, typically a membrane receptor. Those winners are 
amplified for the next round of selection. It is noted that the targets for the selection is 
unknown during the selection; it is verified after the sequence of the aptamer is obtained. 
Cell-SELEX27 significantly enlarged the library of aptamers that bind to cells. It has the 
potential to select aptamers that bind to unknown cells because the selection method does 
not require detailed information about the cells. If tumor cells are used as the targets, 
numerous aptamers that recognize the tumor cells can be selected; novel therapies can be 
developed based on the aptamers. 
6.1.4 Liposomes in sensing 
Besides liposome’s wide applications in drug delivery, it has been reported that 
liposomes can be used to detect mercury by encapsulating a high concentration of 
fluorescein in liposomes. Because of the self-quenching of this dye, the liposome solution 
has a relatively low fluorescent background. The lipids that compose the liposomes have 
been found to have specific interactions with the mercury cations. When Hg2+ binds to 
the lipids, the liposomes are destabilized and the fluorescent dye is released from the 
lipsomes; the localized fluorescein molecules are released evenly in the solution, leading 
to the decrease of the self-quenching effect. As a result, a fluorescence increase is 
detected. The sensing system has high selectivity and specificity. It does not appreciably 
respond to any other divalent metal cations, but Hg2+ concentrations as low as 10 nM lead 
to a detectable fluorescence change. 
Although the system responds to Hg2+, it is not a sensor. The concentration of liposome 
varies from batch to batch, making it difficult to normalize the fluorescence response. 
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However, it is a good platform for the sensing of mercury, and it proves liposomes’ 
potential in heavy metal detection.   
6.1.5 Aptamer functionalized liposome for cisplatin delivery 
Efforts were made to combine the advantages of both liposome and aptamer. Nucleotin 
was chosen as the target. Nucleotin is a bcl-2 mRNA binding protein involved in cell 
proliferation. It is over-expressed in human breast cancer cells such as MCF-7.44-48  
Liposomes were functionalized by AS1411,49 a 26-mer DNA aptamer that recognizes 
nucleotin.44 Once functionalized with AS1411, the lipsomes recognize the breast tumor 
cells. When the liposomes interact with the cells, they fuse, delivering the cisplatin 
encapsulated in the lipsomes to the cells. This leads to cellular death. Because of the high 
specificity of AS1411 for nucleotin and the fact that nucleotin is unique to breast cancer 
cells, this drug delivery system is more cytotoxic to breast cancer cells than other cells. 
 
6.2  Experimental 
6.2.1 Liposome preparation, functionalization and purification 
Liposome preparation:50,51 Stock solutions of HSPC52 (1.25 mg), cholesterol, and 
mPEG2000–DSPE in chloroform were mixed with a 2:1:0.16 molar ratio in a scintillation 
vial. This mixture was blown dry with N2 and further dried under vacuum for at least 6 h. 
The buffer for the liposome preparation contained 25 mM 2-[4-(2-hydroxyethyl)-1- 
piperazinyl]-ethanesulfonic acid (HEPES, pH 7.6), 150 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, and 1 mM CaCl2. This buffer solution (100 mL) containing 3 nmol cholesterol-
tagged DNA (sequence: 5’-GGT GGT GGT GGT TGT GGT GGT GGT GGT TTT TTT 
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TTT TT-cholesterol-3’) was added to the dry lipids. After the mixture had been incubated 
for 6 h at 37 ˚C, liposome-preparation buffer (400 mL) containing 4 mM cisplatin or 50 
mM fluorescein was added. This solution was gently stirred and kept at 37 ˚C for 3 h. 
After that, the solution was stirred and then quickly frozen and thawed for at least 
five cycles. The final solution was incubated at 37 ˚C overnight. The lipid mixture was 
then extruded to form liposomes of approximately 200 nm in diameter by following the 
instructions from Avanti Polar Lipids, Inc. The liposomes were purified on a column 
packed with Sephadex G-100 medium to remove free cisplatin or calcein. 
6.2.2 Fluorecein and cisplatin delivery 
A cell-specific uptake study was done by confocal fluorescence microscopy. The 
MCF-7 and LNCaP cells, cultured as recommended by the American Type Culture 
Collection (ATCC) in Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F-12K 
medium, respectively, were incubated in chamber slides in the medium to allow 70% 
confluence in 12-24 h. The cell medium was removed. The cells were washed with 
prewarmed PBS (1 × 100 mLwell-1) and incubated with prewarmed Opti-MEM medium 
(phenol red reduced) for 30 min before the addition of the liposome solution. Cells were 
further incubated for 5 h or 10 h at 37 ˚C. At the prescheduled times, the cells were 
washed with prewarmed PBS (3 × 100 mLwell-1) and fixed with 4% paraformaldehyde 
solution for 10 min. The cells were washed again with PBS (1 × 100 mL well) and 
analyzed with a confocal fluorescence microscopy. 
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6.3  Results and discussion 
Fluorescein was used in order to evaluate the delivery of the material 
encapsulated in the liposomes to the cells, As shown in Figure 6.2, after the incubation 
with the liposome solution, the dye was successfully delivered into the MCF-7 cells. As a 
comparison, the liposome system cannot deliver dyes to the LNCaP cells. This is because 
the latter do not overepxress nucleotin in their cell membranes. Because the 
concentrations of liposome and cells were low, the interaction between liposomes and 
LNCaP cells are very difficult. 
 
Figure 6.2 Confocal images of MCF-7 (top) and LNCaP (bottom) cells treated with 
NCL-aptamer-functionalized liposomes containing calcein. From left to right: fluorescence 
image, transmission image, and overlay. 
 
Encouraged by the success of the dye delivery, the dye was replaced by the anti-
tumor drug cisplatin. Its cytotoxicity was evaluated by measuring the viability of the cells. 
As presented in Figure 6.3, the viability of the MCF-7 cells decreased by 20% and 60% 2 
and 4 days after the application of the cisplatin-encapsulated liposomes, respectively. No 
significant viability change was observed if the liposome functionalized by DNA 
molecules without affinity for nucleotin was used, which showed that the binding affinity 
124 
 
of the aptamer was essential. The cells that were exposed to liposomes not encapsulating 
cisplatin saw excellent survival rates, indicating that the cytotoxicity of the system was 
from cisplatin, not the DNA aptamer or the liposome. Finally, the system did not affect 
the viability of LNCaP cells. This is consistent with the dye delivery experiment. As the 
material inside the liposomes cannot be delivered into the LNCaP cells, the viability was 
not affected.  
 
Figure 6.3 Cell viability assays for different liposome/cell combinations. Viability 
measurements were taken at day 2 and day 4 of the liposome/cell incubation. Columns 1 
and 2: MCF-7 cells treated with NCL-aptamer-functionalized liposomes loaded with 
cisplatin; columns 3 and 4: MCF-7 cells treated with a control group of DNA-functionalized 
liposomes loaded with cisplatin; columns 5 and 6: MCF-7 cells treated with NCL-aptamer-
functionalized liposomes with no cisplatin; columns 7 and 8: LNCaP cells treated with 
NCL-aptamer-functionalized liposomes loaded with cisplatin. 
 
DNA can be programmed because the interaction of DNA molecules is much 
more predictable than protein interactions. One of the advantages of this drug delivery 
system over the antibody-based system is that the rate of drug delivery can be controlled 
by introducing the antisense sequence of the aptamer strand. This is useful in the case of 
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over-dosing. In most cases, the dosing of a new medicine is difficult to decide and over-
dosing is common and dangerous. However, if over-dosing happens when using this 
system, the anti-aptamer can be applied.  This will decrease the affinity of the aptamer for 
the tumor cells, which will in turn decrease the drug delivery efficiency and minimize 
any side effects from over-dosing. 
 
Figure 6.4 (A) Effect of the concentration of the anti-aptamer on the viability of MCF-7 
cells treated with the functional liposomes. (B) Time-dependent effect of the anti-aptamer 
on the viability of MCF-7 cells treated with the functional liposomes.  
 
Figure 6.4A presents the cell viability after the cisplatin-encapsulated liposomes 
and anti-aptamer have been applied with various concentrations. If more than four 
equivalents of anti-aptamer were applied, the cytotoxicity of the cisplatin could be 
minimized (“rescue effect”). Figure 6.4B indicated that the “rescue” effect of anti-
aptamer is time-dependent. If the anti-aptamer was applied immediately after the 
application of the cisplatin-containing liposomes, almost all the cells could be “rescued.” 
However, there was almost no “rescue” effect if there was a 5-h interval between the 
applications of the liposomes and the anti-aptamer. 
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6.4  Conclusion and perspective 
The liposome was successfully functionalized by the DNA aptamer AS1141, 
which binds to nucleotin, a protein that is over-expressed in human breast cancer cells. 
The liposomes can specifically deliver fluorescent dye to the cells. If cisplatin was 
encapsulated, MCF-7 cells could be specifically killed without affecting the viability of 
LNCaP cells which lack nucleotin in the cell membrane. Control experiments indicated 
that the drug delivery effect was due to the specific interaction between the aptamer and 
breast cancer cells. 
An anti-aptamer sequence was applied as a “rescue” in case of over dosing. If 
more than four equivalents of the anti-aptamer were applied, only trivial cytotoxicity was 
observed. However, the time of the application of the anti-aptamer is critical. An interval 
of less than 5 hours between the applications of the liposomes and anti-aptamers is 
required to produce the “rescue” effect. 
Although this drug delivery system successful delivered cisplatin to breast cancer 
cells, more research must be performed before it can be used in clinical practice. First, the 
retention time of DNA molecules is typically several minutes. If this system is used in 
vivo in its current form, the DNA aptamer will be degraded before it reaches the tumor 
region. This problem can be solved by PEGylating or methylating the DNA aptamer, or 
using L-DNA. Another problem is cost. Cholesterol-conjugated DNA is costly, which 
induces a concern for in vivo applications. Despite the difficulties, the system presented 
in this chapter provided a promising approach to realize targeted drug delivery by 
liposomes. 
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